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A. Synopsis 
 
The incidence of high grade B cell lymphoma in western countries has increased over the last 
decades. Improvement of conventional chemotherapy regimens has significantly contributed 
to prolonged 5-year survival rates which currently reach around 60%. However, relapse after 
conventional chemotherapy is an important challenge, especially in high grade B cell 
lymphomas. The potential benefit of immunological approaches for the elimination of such 
lymphomas still remains unclear. In this study, we attempted to address whether the forced 
expression of foreign antigens in a tumor of B cell origin leads to immune recognition and 
elimination of the tumor and to assess the potential role of IFN-gamma (IFN-γ) in tumor 
rejection. To this end, we used a transgenic mouse lymphoma model, where the human proto-
oncogene c-myc (a foreign antigen for the mouse host) is under the control of regulatory 
elements of the immunoglobulin lambda locus, thereby recapitulating the important features 
of a t(8;22) translocation as found in human Burkitt’s lymphoma. From these spontaneously 
developing tumors, lymphoma cell lines were established that either express (line 291) or are 
deficient (line 9) in Stat1- a key signaling molecule in the response to interferons. We found 
that the expression of foreign antigens such as chicken ovalbumin (OVA) and green 
fluorescent protein (GFP) in Stat1-competent 291 cells led to immune responses that delayed 
tumor progression and improved survival of wild-type animals. Consistent with this, loss of 
foreign antigen inevitably led to accelerated tumor progression upon transfer into 
immunocompetent wild-type mice. Transfer of immunogenic 291-OVA-GFP lymphoma cells 
led to increased tumor progression without loss of foreign antigen upon transfer into IFN-γ-/- 
and Stat1-/- mice indicating that no selection of antigen loss-variants occurred in these mice. 
The rejection of 291-OVA-GFP cells in wild-type mice was at least in part mediated by CD8+ 
T cells as measured by enrichment of the OVA antigen-derived MHC class I-restricted 
SIINFEKL epitope-specific cells in wild-type recipients.. Interestingly, Stat1-deficient 
lymphoma cells (9-GFP and 9-OVA-GFP) were rejected by immunocompetent UBQ-GFP 
transgenic wild-type C57BL/6 mice irrespectively of the presence of a foreign antigen, 
indicating the existence of immunosurveillance against these Stat1-deficient lymphomas. To 
evaluate the key players behind lymphoma rejection, we transferred 9-GFP cells into IFN-γ-/- 
and Stat1-/- recipients. This led to enhanced tumor growth indicating that endogenous IFN-γ 
production and Stat1 signaling are critical for tumor rejection. To gain an insight into the 
mechanistic aspects of innate immunosurveillance against the Stat1-competent and Stat1-
deficient lymphomas, NK cell functionality was evaluated. We found that NK cells could 
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efficiently lyse both Stat1-competent and Stat1-deficient lymphoma cell lines in vitro. 
Treatment with IFN-γ increased the susceptibility of Stat1-deficient lymphoma cells to NK 
cell killing, but decreased that of Stat1-competent cells, presumably by upregulating MHC 
class I expression. The results of this work show that host IFN-γ and Stat1 signaling are 
important for tumor clearance, and that paradoxically, the absence of Stat1 within the 
lymphoma is required for rejection. The data suggest a dual role for Stat1 in the tumor cells: it 
is required for T cell mediated rejection of tumors expressing foreign antigens. Yet, if no 
foreign antigen is expressed, it acts as an oncogene and is required for outgrowth of a tumor 
in an immunocompetent host, presumably by allowing NK cells to be efficiently inactivated 
by the tumor cells.  
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B. List of Abbreviations 
 
BL  Burkitt’s lymphoma 
BSA Bovine serum albumin 
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NK Natural killer cell 
NKT Natural killer T cell 
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RAG-1 Recombination activating gene 1 
STAT Signal transducer and activator of transcription 
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1. Introduction       
1.1 Lymphomas of B cell origin 
Disruption of the physiological balance between cell death and proliferation is a common 
feature of cancers. According to the mechanisms through which the imbalance is achieved, 
human B-cell lymphomas can be grouped into low and high growth fraction lymphomas. 
Lymphomas and leukemia are a group of different types of cancers of the lymphoid system, in 
which distinctive molecular alterations are observed. Low growth fraction B cell lymphomas 
including follicular lymphoma (FL), marginal zone lymphomas (MZLs), mantle cell 
lymphoma (MCL), and B-cell chronic lymphocytic leukemia (B-CLL), are distinguished by 
small cell size, low proliferative index, formation of large tumoral masses in lymph nodes and 
clinical stages associated with low clinical aggressivity (Seng and Peterson, 1997; Capello 
and Gaidano, 2000). A different picture is commonly observed in high-growth fraction B cell 
lymphomas such as large B cell lymphoma (LBCL) and Burkitt’s lymphoma (BL). These 
tumors are associated with an increased proliferative index and larger cell size and are 
clinically more aggressive as a consequence of alterations in key cell cycle regulators such as 
BCL6 or c-MYC (Sanchez-Beato et al., 2003). The different B cell lymphomas and their 
distinct alterations in the molecular patterns are indicated in Table 1. 
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Lymphoma   Gene Function Alteration Frequency 
(%) 
Reference 
FL BCL2 Apoptosis 
inhibition 
 t(14;18) 70-90 (Yunis et al., 
1987) 
MALT 
lymphoma 
BCL10 Apoptosis 
inhibition 
through NF-kB
 
 t(1;14) 
 
   50 
(Willis et al., 
1999) 
MCL Cyclin D1 G1/S cell cycle 
transition 
 t(11;18) 
 
   90 (Levine et 
al., 1989) 
B-CLL Unknown Unknown  13q14 
deletion 
 50-60 (Kalachikov 
et al., 1997) 
LPL PAX5 B-cell 
differentiation 
 t(9;14)   50 (Iida et al., 
1996) 
LBCL BCL6 B-cell 
activation and 
differentiation, 
cell cycle 
control 
  
 t(3;N) 
 
  30-40 
(Lo Coco et 
al., 1994) 
BL c-myc Differentiation, 
cell cycle 
control, 
apoptosis 
induction, 
Adhesion 
 
 t(8;14) 
 t(8;22) 
 t(2;8) 
 
   80 
   10 
   10 
  
(Taub et al., 
1982; Boxer 
and Dang, 
2001) 
Table 1 B cell lymphomas and their defining molecular characteristics 
FL-‘Follicular lymphoma’, MALT-‘Mucosa associated lymphoid tissue lymphoma’, MCL- 
‘Mantle cell lymphoma’, B-CLL-‘B cell chronic lymphocytic leukemia’, LPL- 
‘lymphoplasmacytic lymphoma’, LBCL-‘large B-cell lymphoma’ and BL-‘Burkitt’s 
lymphoma’. 
1.2 Burkitt’s Lymphoma 
Burkitt’s lymphoma (BL), first described by Denis Burkitt as a clinical entity in African 
children, is the first human tumor whose pathogenesis could be linked both to an oncogenic 
virus, Epstein-Barr Virus (EBV), and to the activation of a specific cellular oncogene namely 
c-myc. Three epidemiologically distinct forms of BL are now recognized. The high-incidence 
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‘endemic’ form typically presents as a jaw and/or abdominal tumor in children in tropical 
areas of equatorial Africa and Papua New Guinea. Elsewhere, BL occurs in ‘sporadic’ form 
mainly in children at intermediate to low incidence. Remarkably, a third, adult form of the 
tumor, AIDS-BL proved to be very common among HIV-infected individuals. All forms of 
BL show a similar histological appearance, with malignant population of round monomorphic 
B cells, that gives the tumor histology a ‘starry sky’ pattern. 
1.2.1 Translocations 
Regardless of its geographical origin, Burkitt’s lymphoma is invariably characterized by 
chromosomal translocations juxtaposing the c-myc protooncogene (on chromosome 8) either 
with regulatory sequences of immunoglobulin (Ig) heavy (H) chain on chromosome 14 
leading to the translocation t(8;14) or with regulatory sequences of Ig light (L) chain genes, 
either Ig kappa (Igκ) on chromosome 2 leading to t(2;8) or Ig lambda (Igλ) on chromosome 
22 leading to translocation t(8;22). All these translocations result in deregulated expression of 
c-myc which is a hallmark of Burkitt’s lymphoma (Dalla-Favera et al., 1982). Accordingly, 
the World Health Organization Classification of Hematologic Malignancies indicates that the 
presence of one of the c-myc/Ig translocations should be considered the gold standard for the 
diagnosis of BL (Harris et al., 1999). 
1.2.2 EBV and Burkitt’s lymphoma 
Epstein-Barr virus (EBV), a gamma 1-herpesvirus carried by the vast majority of individuals 
worldwide as a lifelong asymptomatic infection, has growth-transforming potential and is 
linked with a variety of B cell, T/NK cell and epithelial malignancies (Kelly and Rickinson, 
2007). The high-incidence ‘endemic’ BL form occurring in children of Africa is almost 
always EBV genome-positive whereas in the ‘sporadic’ form, different degrees of EBV 
association are observed. 30-40% of AIDS-BL tumors carry EBV. EBV preferentially infects 
B lymphocytes through the binding of viral envelope glycoprotein gp350 to the CD21 
receptor on the surface of B cells and through the binding of the second glycoprotein gp42 to 
human leukocyte antigen (HLA) MHC class II molecule as a co-receptor (Young and 
Rickinson, 2004). The frequency of EBV’s association with BL (particularly endemic) and 
the fact that all EBV+ BLs (whether endemic, sporadic or AIDS-associated) carry the virus in 
every cell of the malignant clone, imply a definitive role for the virus in the tumor 
pathogenesis. Importantly, EBV has the ability to transform resting B cells into immortalized, 
latently infected lymphoblastoid cell lines (LCLs), which provide an in vitro system for the 
lymphomagenic potential of the virus (Young and Rickinson, 2004) 
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1.2.3 c-myc function in normal cell growth and cancer development 
The c-myc gene was identified as the cellular homologue of the retroviral v-myc oncogene.   
c-myc belongs to the family of myc genes which includes B-myc, L-myc, N-myc and s-myc 
although only c-myc, L-myc and N-myc were found to be involved in neoplasmic diseases 
(Dang, 1999). c-MYC protein is overexpressed in a variety of human cancers including 
approximately 80% of breast cancers, 70% of colon cancers, 90% gynecological cancers, and 
50% of hepatocellular carcinomas. A variety of hematological malignancies also express 
abnormal c-myc levels. The gene is located on human chromosome 8 band q24, consists of 
three exons that give rise to a 64 kDa protein. It has been suggested that both activation and 
repression of genes through c-myc are important for neoplastic transformation (Dang, 1999) 
Targeted deletion of the murine c-myc gene leads to embryonic lethality with growth 
abnormalities in the heart, pericardium, neural tube and a delay or failure in embryonic 
turning, suggesting its role in the normal development (Davis et al., 1993). In normal cells, 
expression of c-myc is tightly-regulated at transcriptional and post-transcriptional level by 
growth factors and external signals. In general, resting cells express very low amounts of c-
MYC protein and the levels increase in response to growth factors leading to entry into the 
cell cycle. The levels return to the basal quiescent state in the resulting daughter cells. Ectopic 
overexpression of c-myc in primary cells leads to the activation of failsafe mechanisms which 
involve the p19/p14ARF and p53-dependent pathways and switch on apoptosis programs to 
prevent uncontrolled growth (Lowe et al., 2004).  
1.2.4 Models for studying Burkitt’s lymphoma 
The involvement of EBV and c-myc in determining disease pathogenesis and progression on 
the one hand and the immunogenicity of the tumor on the other hand has been a subject of 
intensive investigations. To gain insights into the changes imposed by different EBV genes 
and the oncogene c-myc, an in vitro model system that recapitulates important features of 
LCLs and BL cells in vitro has been established which is described in detail in section 1.6.4.  
Previous efforts to develop a mouse model of BL centered on generation of transgenic mice 
that express the c-myc gene under the control of IgH or IgL regulatory sequences. The classic 
experiment from Adams et al., showed that transgenic mice, expressing c-myc gene under the 
control of the intronic immunoglobulin (Ig) heavy chain enhancer, develop monoclonal or 
oligoclonal early pre-B cell lymphoid malignancies (Adams et al., 1985). These constructs 
induced primarily precursor B cell as well as some surface Ig (sIg) positive B cell 
lymphomas. However, the pathological features of the neoplasms were consistent with the 
diagnosis of lymphoblastic lymphoma (LL) rather than BL. In 2000, Kovalchuk et al., have 
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shown that mice transgenic for a human c-myc protooncogene driven by regulatory elements 
of Igλ locus develop lymphomas with striking similarities to human BL. Monoclonal tumors 
with the characteristic starry sky appearance of BL developed from an initially polyclonal 
population of B cells. Lymph nodes and spleens of tumor bearing mice were populated by 
uniform populations of IgM+CD19+CD5-CD23- cells, which is characteristic phenotype of 
human BL (Gerbitz et al., 1999; Kovalchuk et al., 2000). 
1.3 Immune response to tumors 
An increased understanding of the complex interaction of transformed cells and cells of the 
immune system in the late 1950s led to the formulation of the cancer immunosurveillance 
theory by Burnet and Thomas. However, as Burnet and Thomas commented, the caveat with 
the idea of cancer immunosurveillance was that it could not be shown to exist in experimental 
animals (Burnet et al., 1957; Thomas L et al., 1982). This led others to explore the existence 
of cancer immunosurveillance, although the initial studies were inconclusive and failed to 
prove or disprove the existence of cancer immunosurveillance (Klein, 1973; Stutman, 1975). 
With the availability of the mouse models and development of monoclonal antibodies, the 
concept of cancer immunosurveillance has recently been validated (Smyth et al., 2001b; Dunn 
et al., 2002; Dunn et al., 2004). 
Additional studies demonstrated that the immune system may not only be involved in tumor 
elimination but also promote the development of primary tumors with reduced 
immunogenicity that allows escape from immune recognition (Shankaran et al., 2001). This 
led to the formation of another, yet more refined hypothesis termed as “cancer 
immunoediting” encompassing host-protective and tumor-sculptive actions of the immune 
system during tumorigenesis. 
1.3.1 Cancer immunoediting 
The ability of the immune system to control and shape tumors, termed cancer immunoediting, 
is the result of three processes that function either independently or in a sequence of three 
phases namely, elimination (cancer immunosurveillance, in which the immune system 
functions as extrinsic tumor suppressor in the naïve host), equilibrium (expansion of 
transformed cells is held in check by the immune system) and escape (emergence of tumor 
cell variants with impaired immunogenicity which later grow into macroscopic tumors). 
1.3.2 Elimination phase 
One approach for testing the role of the immune system in controlling tumor development is 
to remove specific components of the mouse immune system and monitor the mice for the 
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development of tumors. Predominantly through the use of gene-targeted mice, such an 
approach has demonstrated that a number of immune cells including those of the innate and 
adaptive system are important for the suppression of tumors. For example, studies on BALB/c 
and C57BL/6 mice revealed that natural killer (NK) and natural killer T (NKT) cells also 
participate in cancer immunosurveillance (Smyth et al., 2001a). Studies in spontaneous tumor 
models of B cell lymphomas in mice lacking perforin and beta 2 microglobulin (β2m) have 
revealed that such lymphomas can be rejected by NK cells and γδ T cells following 
transplantation into WT mice. These studies demonstrated that cell surface expression of 
MHC class I molecules by tumor cells is important in determining which effector cells 
mediate protective effects (Street et al., 2004). Many of the hypotheses of cancer 
immunosurveillance were validated in models of chemical carcinogenesis. The most 
commonly used carcinogen-induced tumor models are fibrosarcomas induced using MCA 
(methylcholanthrene). Recombination activating gene (Rag2-/-) and Severe Combined 
Immunodeficiency (SCID) mice, both of which lack an adaptive immune system display an 
increased incidence of tumor formation indicating that both αβ T cells and γδ T cells are 
found to be important in tumor suppression (Shankaran et al., 2001). Studies on IFN (Dighe et 
al., 1994; Kaplan et al., 1998; Shankaran et al., 2001) demonstrated that deficiencies in key 
immunological cytokines and signal transducers such as IFN-γ and Stat1 resulted in higher 
susceptibility to chemical carcinogens. The different mouse models which were used to study 
immunosurveillance against tumors are shown in table 2. 
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Table 2 Increased susceptibility of immunodeficient mice to carcinogen-induced and 
spontaneous tumors 
Various contemporary studies of mice with molecularly defined inactivating defects in innate and 
adaptive immunity have shown that immunodeficient mice do develop more spontaneous and 
carcinogen-induced tumors than their immunocompetent counterparts. This table depicts the various 
immunodeficent mice used to examine the cancer immunoediting hypothesis. MCA 
(methylcholanthrene) is widely used as chemical carcinogen in the above mentioned studies. B16-
OVA is a mouse melanoma tumor engineered to express chicken ovalbumin as foreign antigen.Stat1-/- 
Tp53-/- is Stat1 and p53 tumor suppressor double knock out mice  
Mice Immune 
phenotype 
Tumor 
phenotype 
Reference 
Rag1-/- or Rag2-/- 
 
 
 
 
 
Rag2-/-γc-/- 
 
 
 
 
 
IFN-γ-/- 
 
 
 
 
 
 
 
 
IFN-γR1-/- 
 
 
 
Stat1-/- 
 
 
 
 
 
Rag2-/-Stat1-/- 
 
 
 
 
 
lack T cells, B cells, 
NKT cells but posses 
functional NK cells 
 
 
 
lack T cells and B 
cells, NKT and NK 
cells 
 
 
 
Lack IFN-γ 
 
 
 
 
 
 
 
 
Insensitive to IFN-γ 
 
 
 
Insensitive to IFN-α, 
IFN-β and IFN-γ 
 
 
 
 
Lacks T cell, B cells, 
NKT cells. 
Insensitive to IFN-α, 
IFN-β and IFN-γ 
 
↑ MCA induced 
sarcomas 
 
 
 
 
↑ B cell tumors 
 
 
 
 
 
↑ MCA induced 
sarcomas, 
↑ Spontaneous 
disseminated 
lymphomas 
↑ B16-OVA 
melanoma formation 
 
 
↑ MCA-induced 
sarcomas 
 
 
↑ MCA induced 
sarcomas, 
Wider tumor range in 
Stat1-/-Tp53-/- mice 
 
 
↑ MCA induced 
sarcomas, 
↑ Spontaneous 
intestinal and 
mammary neoplasms 
(Shankaran et al., 
2001; Dunn et al., 
2006) 
 
 
 
(Kovacic et al., 2006)
 
 
 
 
 
(Kaplan et al., 1998; 
Shankaran et al., 
2001; Schuler and 
Blankenstein, 2003) 
 
 
 
 
 
(Qin and 
Blankenstein, 2000) 
 
 
(Kaplan et al., 1998; 
Shankaran et al., 
2001; Kovacic et al., 
2006) 
 
 
(Shankaran et al., 
2001; Dunn et al., 
2006) 
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1.3.3 Equilibrium phase 
The elimination phase of the cancer immunoediting process leads to the eradication of a 
significant proportion of transformed cells but the tumor cells exist in a period of latency 
extending from the end of the elimination phase until the start of the escape phase which 
ultimately results in the emergence of detectable malignant disease. It is also hypothesized 
that during the equilibrium phase, the tumor cells acquire enormous plasticity which allows 
them to grow in immunocompetent animals (Lengauer et al., 1998). However, the whole 
process is terminated if the elimination process in immunoediting is successful at destroying 
the developing tumor. In a recent study of mouse models of primary carcinogenesis, Schreiber 
and colleagues have demonstrated that neoplastic cells in equilibrium are transformed but 
proliferate poorly in vivo. Furthermore, they showed that the elimination phase requires the 
action of both innate and adaptive immunity and the equilibrium is maintained solely by the 
adaptive immune system (Koebel et al., 2007).The three phases of the cancer immunoediting 
process are shown in figure 1. 
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Figure 1 Three Es of cancer immunoediting 
Cancer immunoediting comprises three phases. a) Elimination generally indicates the 
immunosurveillance where different immune cells encounter the tumor and control tumor growth. b) 
Equlibrium refers to the process in which the immune system selects and promotes the generation of 
tumor cells or antigen loss variants with increased capacity to survive the immune attack. c) Escape is 
the process wherein the immunologically sculpted tumor expands in an uncontrollable manner. In a 
and b, developing tumor cells (blue), tumor cell variants (red) and underlying stroma and non-
transformed cells (grey) are shown; in c, additional tumor variants (orange) that have formed as a 
result of the equilibrium process are shown. Different lymphocyte populations are as marked. The 
small orange circles represent cytokines and the white flashes represent cytotoxic activity of 
lymphocytes against tumor cells (Adapted from Dunn GP et al., 2002).  
1.3.4 Escape phase 
When malignant growth is tightly prevented due to immune recognition, tumors should be 
eliminated. Their persistence in immunocompetent hosts demonstrates the beginning of an 
escape process - the third phase in the cancer immunoediting model. Many studies have 
shown that tumor escape can be a direct consequence of alterations occurring in edited tumors 
themselves. During the escape period it is envisaged that tumor cells accumulate further 
changes (such as DNA mutations and changes in gene expression) that can modulate the 
expression of tumor-associated antigens (TAA) and as this process continues, the immune 
system exerts a selective pressure by eliminating susceptible tumor clones. The pressure 
exerted by the immune system is often sufficient to control tumor growth. But if the immune 
response fails to completely eliminate the tumor, this results in the selection of tumor cell 
variants that are able to resist, avoid or suppress the anti-tumor immune response leading to 
tumor escape. In this line it has been shown that malignancies develop due to either direct or 
indirect alterations in antigen processing and presentation that render them invisible for T 
cells (Seliger et al., 2000a; Seliger et al., 2000b). In addition, loss of tumor-specific antigen as 
escape mechanisms was seen not only in naturally occurring but also in the therapeutic 
vaccination settings. Although adoptive transfer of T cells specific for tumor antigens such as 
CD4
CD4
CD4CD4
CD8
CD8
CD8
CD8
NK NK
NKT
EquilibriumElimination Escape
Genetic instability/tumor heterogeneity
immune selection
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Melanoma antigen recognized by T cells (MART-1)/Melan A or gp100 together with IL-2 
leads to better clinical responses in metastatic melanoma, investigators have observed loss of 
antigens in progressive melanomas (Yee et al., 2002). In recent years, NK cell-mediated 
tumor surveillance has been shown to be important for tumor rejection and a recent study 
demonstrated that human tumors secrete soluble forms of MHC class I chain related (MIC) 
NKG2D ligands leading to downregulation of NKG2D receptor on effector cells and 
subsequently resulting in attenuated cytotoxicity functions (Groh et al., 2002). In addition, 
studies have shown that depletion of CD4+CD25+ regulatory T cells (Tregs) by using an anti-
CD25 monoclonal antibody enabled mice to reject tumors that grew progressively in control 
mice (Shimizu et al., 1999) indicating that tumors might induce regulatory T cell phenotypes 
and exploit this to escape immune responses. 
1.4 Foreign antigen-mediated tumor rejection 
Tumors are caused by the progressive growth of the progeny of single transformed cells. 
Treatment of tumors requires that all malignant cells be either removed or destroyed without 
affecting normal cells. An attractive way of achieving this goal is to induce an immune 
response against the tumor that would discriminate between tumor cells and their normal 
counterparts. Immunological approaches to the treatment of tumors have been attempted over 
several years but the success rates are variable and often inconsistent. In general, during the 
development of T cells, only those thymocytes whose receptors interact weakly with self 
antigen-MHC complexes receive a signal that enables them to survive. This is called positive 
selection. Thymocytes whose receptors bind and react strongly to self antigens receive signals 
that lead to their death, a process called ‘negative selection’. These two selection processes 
allow for the establishment of cellular immunity that can recognize foreign antigens presented 
by self MHC molecules and at the same time eliminate potentially self-reactive thymocytes, 
thereby establishing immunological tolerance to ubiquitous self antigens. In spontaneously 
developing tumors, the immune system is challenged with a dilemma, namely that proteins 
present in cancerous cells are largely normal self proteins. Some of these proteins, however, 
are altered self proteins. As such mutations in proteins might give rise to peptides that are not 
presented in normal self tissues; the immune system may selectively recognize tumor cells. 
Furthermore, in some tumors normal proteins are overexpressed thereby allowing the immune 
system to discriminate between normal and aberrant cells by the mere fact that aberrant cells 
produce and therefore present those overexpressed proteins to higher levels than normal cells. 
The recognition of self proteins presented in abnormal levels or in abnormal forms is believed 
to be due to the fact that the negative selection of thymocytes is not absolute. Indeed the 
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success stories of adoptive T cell transfer for the treatment of malignant melanoma 
demonstrate that self antigens expressed in abnormal levels can be efficiently targeted by the 
immune system. Nevertheless, tumors expressing foreign antigens are better targeted by the 
immune system as exemplified by numerous virus-associated tumors. T cell reactivity against 
foreign antigens is clearly stronger than against self antigens. It is widely believed that the 
presence of foreign antigens is crucial for eliciting strong immune responses against tumors. 
The role of different components of the host immune system involved in suppression of tumor 
progression has been under intense investigation. The CD8+ T cells recognize fragments of 
intracellular proteins in the form of peptides of 8-10 amino acids complexed with MHC class 
I molecules (Townsend et al., 1986; Townsend and Bodmer, 1989). Studies from Mc Cabe et 
al have shown that recombinant vaccinia virus expressing the minimal determinant as well as 
the full length ovalbumin protein elicited the specific lytic response in C57BL/6 mice against 
EG.7OVA, a transfectant of the murine thymoma EL4 cell line expressing ovalbumin (Zhou 
et al., 1992; Minev et al., 1994; McCabe et al., 1995). Stimulating these effectors in vitro with 
OVA257-264 peptide induced H-2Kb restricted CD8+ T cells that not only lysed but also 
specifically secreted IFN-γ in response to the antigen. Furthermore, the growth of established 
ovalbumin transfected tumors in a pulmonary metastasis model system was significantly 
reduced upon adoptive transfer of anti-OVA257-264 CD8+ T cells (McCabe et al., 1995). 
Moreover, using the B16 melanoma model, which expresses OVA as a surrogate tumor 
antigen, Schüler et al. have shown that CD8+ effector T cells recognize the antigens directly 
on tumor cells and that tumor rejection requires IFN-γ (Schuler and Blankenstein, 2003). 
Despite the cancer cell’s expression of immunogenic molecules, the host does not always 
mount an effective immune response to these antigens. A number of groups have conducted 
experiments in which highly immunogenic foreign antigens such as hemagglutinin from 
influenza A virus (Staveley-O'Carroll et al., 1998), the β-galactosidase (β-gal) from E.coli 
(Wang et al., 1995) and the ovalbumin protein from chicken (McCabe et al., 1995) were 
expressed in tumor cells. The results obtained using different foreign antigens are fairly 
uniform; tumors tend to grow progressively, retaining their lethality despite of the expression 
of foreign and highly immunogenic proteins by the tumor cells (Restifo et al., 2002). It is not 
yet known whether targeting ‘self’ or foreign antigens will be more successful in the 
immunotherapy for cancer. Some researchers have asserted that mutated tumor-associated 
antigens (TAA) are superior targets for vaccine design because immune cells will not be 
tolerized to these antigens. However, recent work from Hy Levitsky’s and Linda Sherman’s 
groups has shown that even the most immunogenic ‘foreign’ antigen, such as hemagglutinin 
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(HA) antigen from influenza A virus can be tolerizing when expressed peripherally (i.e. 
outside the thymus) either in normal cells or in tumor cells (Staveley-O'Carroll et al., 1998; 
Morgan et al., 1999). The different foreign antigens used in studies are shown in table 3. 
 
Tumor model Foreign antigen Experimental 
outcome 
Reference 
 
Colon carcinoma 
CT26 
 
 
 
A20 B cell 
lymphoma 
 
 
 
EG7-Thymoma 
 
 
 
 
β-galactosidase from 
E . coli 
 
 
 
Hemagglutinin from 
influenza 
 
 
 
Ovalbumin from 
chicken 
 
Delay in tumor 
progression and 
improved survival 
 
 
Induction of T cell 
anergy during tumor 
progression 
 
 
Reduction of growth 
of established tumors 
 
(Wang et al., 1995) 
 
 
 
 
(Staveley-O'Carroll 
et al., 1998) 
 
 
 
(McCabe et al., 
1995) 
Table 3 Different foreign antigens used in tumor models and their experimental outcome. 
 
1.5 Role of interferons in cancer surveillance 
Interferons (IFNs) are a family of proteins originally identified by their ability to protect cells 
from viral infections. Depending on the structural basis and the stimuli that induce their 
expression, IFNs have been divided into type I and type-II interferons. Type I IFNs are 
produced in response to viral infections and are subclassified into IFN-α and IFN-ß (Pestka et 
al., 1987). The only type-II interferon, IFN-γ, is produced by T lymphocytes, NKT cells and 
NK cells (Farrar and Schreiber, 1993; Boehm et al., 1997). The interferon signaling pathway 
is shown in figure 2. 
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Figure 2: Overview of Interferon Signaling 
Interferon-γ (IFN-γ; type II IFN) induces the dimerization of the IFN-γ receptor subunits, IFNGR1 and 
IFNGR2, which leads to the activation of the Janus kinases Jak1 and Jak2 that are constitutively 
associated with these subunits. The Jaks phosphorylate a crucial tyrosine residue of IFNGR1, forming 
a Stat1 (signal transducer and activator of transcription 1)-binding site; they then tyrosine 
phosphorylate receptor-bound Stat1. Stat1 homodimers enter the nucleus and bind promoters at IFN
-activated sites (GASs) and induce gene transcription. The type I IFNs (IFN  and IFN ) bind a 
receptor that consists of the subunits IFNAR1 and IFNAR2, which are constitutively associated with 
tyrosine kinase 2 (Tyk2) and Jak1, respectively. Activated Tyk2 and Jak1 phosphorylate Stat1 or 
Stat2. Stat1 and Stat2 associate with the cytosolic transcription factor IFN-regulatory factor 9 (IRF9), 
forming a trimeric complex known as IFN-stimulated gene factor 3 (ISGF3). On entering the nucleus, 
ISGF3 binds IFN-stimulated response elements (ISREs). Courtesy of Mario Köster, HZI 
Braunschweig.  
1.5.1 IFN-γ in tumor immunity 
Recent experiments performed in various animal models lacking either IFN-γ (Dalton et al., 
1993), IFN-γ receptor (Huang et al., 1993; Lu et al., 1998), or IFN-γ signaling components 
have emphasized the importance of IFN-γ in tumor rejection. In most of these animal models, 
IFN-γ was shown to be involved in the tumor rejection as blocking endogenous IFN-γ by 
administrating neutralizing antibodies inhibited tumor rejection (Dighe et al., 1994). 
Moreover, in adoptive transfer tumor models, the efficiency of CD8+ T cells in mediating 
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tumor rejection was directly proportional to the production of IFN-γ (Barth et al., 1991; 
Becker et al., 2001). It has been shown that the injected CD8+ T cells can eradicate 
established melanoma tumors and that rejection was mediated by IFN-γ producing T cells. 
Interestingly, the release of IFN-γ had two crucial functions. First, it inhibited tumor 
angiogenesis and second, it increased MHC class I expression on tumor cells (Meunier et al., 
2005).  
Many of the functions of IFN-γ on tumor growth were identified in animal models using 
chemical carcinogenesis such as MCA. Experiments performed in the interferon unresponsive 
host (Stat1-/- mice) showed that these animals were highly sensitive to MCA-induced primary 
tumors. These tumors grew progressively when transplanted into IFNγ-/- animals but were 
rejected when transplanted into a WT immunocompetent host (Shankaran et al., 2001). These 
experiments demonstrated that IFN-γ responsiveness on the host side is a prerequisite for 
tumor elimination. The experiments did not address the question whether the tumor cells were 
direct targets of IFN-γ. Immunogenic MCA-induced tumor cells derived from Rag2-/- mice 
were rejected when injected into naïve immunocompetent recipients (Shankaran et al., 2001). 
Surprisingly, when the IFN-γ responsiveness of these cells was abolished by expressing the 
dominant negative IFNγR1 mutant, then the cells grew progressively in wild-type mice 
(Dighe et al., 1994). It has been shown that tumors derived from IFNγR1-/- mice are poorly 
immunogenic. These tumors become immunogenic when interferon signaling was restored by 
expression of IFNγR1 (Kaplan et al., 1998). Moreover IFNγR1-/- tumor cells were rendered 
immunogenic by expressing IFN-γ inducible components involved in antigen processing and 
presentation (Shankaran et al., 2001). The data argue that IFN-γ exerts its function by directly 
acting on the tumor by increasing the immunogenicity and/or exerting anti-proliferative 
effects. Conflicting data with respect to the action of IFN-γ derives from Qin and 
Blankenstein. When MCA-induced fibrosarcomas derived from IFNγR1-/- mice were 
reconstituted with IFNγR1, the tumor cells were rejected but only in IFNγR competent hosts. 
The expression of IFNγR in the tumor cells was not of relevance. The authors concluded that 
IFNγR expression in the tumor cells is not necessary for an antitumor response whereas the 
IFNγR expression within the host cells is important for the generation of an antitumor 
response (Qin and Blankenstein, 2000). 
As shown in figure 2, the binding of the cytokine to its cell surface receptor results in receptor 
dimerization and the subsequent activation of Stat proteins. After dimer formation, Stat 
proteins translocate to the nucleus, where they induce or modulate the expression of target 
genes (Bromberg and Darnell, 2000; Levy and Darnell, 2002). The binding of IFN-α to its 
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receptor activates two receptor-associated Janus kinases, Jak1 and Tyk2, which phosphorylate 
the cytoplasmic tails of the interferon receptor subunits IFNAR-1 and IFNAR-2 on specific 
tyrosine residues. These phospho-tyrosine residues provide docking sites for the transcription 
factors of the Stat family which are phosphorylated after ligand binding (Haque and Williams, 
1998; Leonard and O'Shea, 1998). IFN-α signaling leads to the formation of interferon 
stimulated gene factor 3 (ISGF3), a DNA binding complex that consists of Stat1-α (or Stat1-
β, an inactive form), Stat2 and p48 DNA binding protein known as interferon regulatory 
factor 9 (IRF-9) (Darnell et al., 1994). 
Increasing evidence suggests that Stat1 acts as a tumor suppressor and seems to play an 
important role in the regulation of tumor surveillance (Kaplan et al., 1998; Shankaran et al., 
2001; Lesinski et al., 2003; Badgwell et al., 2004). Stat1-/- mice are prone to develop solid 
tumors and the tumor suppressing activity of Stat1 was attributed to its role as a key 
transcription factor in the interferon signaling pathway. Mice deficient in Stat1 display no 
developmental abnormalities but completely lack responsiveness to type I and type II 
interferons (Durbin et al., 1996; Meraz et al., 1996). Stat1 is found to be inactive or deficient 
in many human tumors (Wong et al., 1997; Abril et al., 1998; Sun et al., 1998; Pansky et al., 
2000). Other studies have shown that Stat1 is constitutively expressed in tumors (Bowman et 
al., 2000). Stat1 is not just activated by IFNs but also by a variety of cytokines such as IL-6, 
IL-10, growth hormone, leukemia inhibitory factor (LIF), epidermal growth factor (EGF) and 
platelet-derived growth factor (PDGF) (Ruff-Jamison et al., 1993; Silvennoinen et al., 1993; 
Raz et al., 1994). It is evident that cytokines and growth factors might interfere with tumor 
growth. It has been shown that Stat1 expression by tumor cells is a negative regulator for 
tumor angiogenesis and proliferation (Huang et al., 2002). Using fibrosarcoma RAD-105 cells 
derived from Stat1-/- mice, the reconstitution of Stat1 expression results in a reduction of pro-
angiogenic molecules such as bFGF, MMP-2 and MMP-9, suggesting that Stat1 negatively 
regulates tumor angiogenesis.  
1.5.2 Stat1 as tumor promoter for leukemia development 
In a recent study, this tumor-suppressive role of Stat1 was challenged. Using a model of v-abl 
induced B-cell leukemia, it was shown that Stat1 functions as a tumor promoter and induces 
hematopoietic malignancies (Kovacic et al., 2006). This study suggests that low MHC class I 
expressing tumor cells enable NK cell lysis and account for increased tumor clearance, but 
paradoxically they found that Stat1-/- tumor cells acquired increased MHC class I expression 
upon leukemia progression (Kovacic et al., 2006). 
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1.6 Immunosuppressive strategies of tumor cells 
Despite increasing knowledge of the regulation of anti-tumoral immune responses, tumor 
immunotherapy is still unsuccessful. Studies from pre-clinical mouse models have shown that 
cells of the innate and adaptive arm of the immune system can mediate anti-tumoral functions. 
However, tumors have developed strategies to counteract immunological recognition or 
effector functions. 
1.6.1 Abnormalities in antigen presentation machinery 
A major mechanism that allows tumor cells to evade T cell recognition is impaired antigen 
presentation (Marincola et al., 2000). This is achieved by defects in antigen processing and 
involves components of the immunoproteasome (LMP2 and LMP7) or the transporter 
associated with antigen processing. Moreover, low expression, selective loss of individual 
HLA alleles or complete absence of MHC class I expression due to mutations in the ß2-
microglobulin gene, are considered hallmarks in tumor progression. 
1.6.2 Secretion of immunosuppressive factors 
Transforming growth factor ß (TGF-ß), an immunosuppressive cytokine inhibits T cell 
activation, differentiation and proliferation (Li et al., 2006), and blockade of TGF-ß signaling 
allows the generation of otherwise repressed tumor-specific T cells (Gorelik and Flavell, 
2001). Recent experiments have shown that TGF-ß acts on CTLs to specifically repress the 
expression of different cytolytic gene products such as perforin, granzyme A, granzyme B, 
Fas-L and IFN-γ, which are collectively responsible for CTL mediated cytotoxicity (Thomas 
and Massague, 2005). In addition to TGF-ß, other biologically active agents such as IL-10 
present within the tumor microenvironment impair immune cell functions, including dendritic 
cells (Gerlini et al., 2004), and it has been demonstrated that IL-10 protects the tumor from 
CTL mediated cytotoxicity by downregulating TAP-1 and TAP-2 (Kurte et al., 2004). 
1.6.3 Tumor-induced antigen-specific CD8+ T cell tolerance 
Immunological tolerance is established not only in the thymus but also in the periphery. 
Several mechanisms have been proposed for the establishment of peripheral tolerance 
including the presentation of antigen in the absence of co-stimulatory molecules or in the 
presence of T cell suppressive cytokines. Furthermore, T cells in the periphery are known to 
be rendered unresponsive against their cognate antigen, which is also referred to as T cell 
anergy. It has long been speculated that tumors might escape immunological surveillance 
through the induction of peripheral T cell tolerance and anergy. In support of this concept, the 
transfer of antigen-specific T cells into tumor-bearing mice caused phenotypic changes in the 
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transferred T cells as determined by their poor cytolytic and proliferative capacities (Otten 
and Germain, 1991; Lee et al., 1999). . 
1.6.4 MYC overexpression imposes non-immunogenic phenotype on human B cells 
When primary EBV infection leads to virus-driven proliferation of LCL-like cells in vivo, as 
seen in patients with infectious mononucleosis, these cells elicit strong EBV specific CD8+ T 
cell response (Young and Rickinson, 2004). EBV-positive BL and derived cell lines differ 
dramatically from LCLs in their cellular phenotype, growth behavior, and immunogenicity. 
EBV-positive BL cells do not express the activation markers, adhesion molecules, and 
costimulatory molecules typical of LCLs (Gregory et al., 1988; Billaud et al., 1990) and they 
grow as single cell suspension rather than in clumps. Since a major difference between EBV-
positive BLs and LCLs is the expression of c-myc, these findings pointed to the possibility 
that c-myc directly imposes the non-immunogenic phenotype seen in BL cells. For this, LCLs 
were established in which the function of the Epstein-Barr nuclear antigen 2 protein, a key 
transcriptional activator involved in the B cell transformation program, is regulatable by 
estrogen. In the presence of estrogen the cells grow with a LCL phenotype and stop 
proliferating when estrogen is withdrawn (ER/EB2 cells, (Kempkes et al., 1995)). These cells 
were then stably transfected with a constitutively active, Igκ-enhancer driven c-myc gene (A1 
cells, (Polack et al., 1996) or with a tetracycline-regulatable c-myc expression construct 
(P493-6 cells, (Pajic et al., 2000)). In both cell lines c-myc overexpression rendered 
proliferation independent of estrogen and the viral proliferation program, and imposed the cell 
surface phenotype of BL cells. Studies in these conditional cell lines revealed that MHC class 
I, activation markers, and co-stimulatory molecules are highly downregulated during c-myc 
driven proliferation. These c-myc driven cells had not only lost the allostimulatory capacity to 
T cells of the parental ER/EB2 cells in a mixed lymphocyte reaction, they also could not be 
recognized by antigen-specific CD8+ T cell clones even when they were forced to express the 
cognate antigen by infection with recombinant vaccinia virus (Staege et al., 2002). 
Consecutive studies using expression profiling revealed that c-myc not only downregulates 
MHC class I, costimulatory and adhesion molecules, by negatively regulating the NF-κB and 
interferon response it also impairs antigen processing and presentation by downregulating 
components of the immune proteasome and the peptide transporter TAP1 and TAP2 (Schlee 
et al., 2007a; Schlee et al., 2007b). Thus, in this in vitro system, B cells driven into 
proliferation through constitutive or conditional up-regulation of c-myc are immunologically 
silenced in the absence of any immune selection. This implies that non-immunogenicity of 
tumor cells may not necessarily be the result of stepwise immune escape, it may also be 
 28
directly imposed by the oncogenic transformation process. These findings are consistent with 
the observation that EBV-positive and EBV-negative BL show essentially the same non-
immunogenic phenotype. This is a very important feature of BL cells as the viral antigens 
expressed in EBV-positive BLs are foreign antigens and should therefore be easily 
recognized. The key differences between the LCLs and Burkitt’s lymphoma cells are listed in 
figure 3  
Growth pattern
c-myc/Ig translocation   -    +
Expression of viral antigens
EBNA1 +++ +++
EBNA2 +++    -
EBNA-LP +++    -
EBNA 3A, 3B, 3C +++    -
LMP1 +++    -
LMP2 +++    -
Antigen processing & presentation
MHC class-I and class-II +++    +
peptide transporters(TAP1 &TAP2) +++    +
components of immunoproteasome
PA28α & PA28β +++    -
Lmp2 & Lmp7 +++    -
Allo-stimulation +++    -
Susceptibility to CTLkilling +++    -
clumps single cells
*
EBV-LCLs EBV-Burkitt‘s lymphoma
 
 
Figure 3 
Compared to LCLs the immunogenicity of BL cells is severely impaired 
EBV-infected lymphoblastoid cell lines and EBV-positive Burkitt’s lymphoma cells display differences 
in viral antigen expression, cell phenotype and immunological recognition. As indicated in the figure, 
the T cell-mediated elimination of Burkitt’s lymphoma is impaired because of low expression of MHC 
class I, impaired response to interferons, and defects in antigen presentation compared to the highly 
immunogenic LCLs. ‘+++’ indicates high, ‘+’ indicates low and ‘–‘ indicates no expression levels. 
* In about 15% of African Burkitt’s lymphomas the highly immunogenic EBNA3A, -3B, and -3C proteins 
are expressed. 
 29
1.7 Aim of the Study 
The previous studies have revealed unequivocally that rapid proliferation and reduced 
immunogenicity of BL tumors are direct consequences of the activation of the proto-oncogene 
c-myc in vitro, but it remains to be elucidated if the observed effects of c-myc overexpression 
in vitro can be recapitulated in vivo. In this study we aimed to establish a murine model to 
elicit immune responses directed against foreign antigens in high grade B cell lymphomas and 
we addressed the following questions:  
 
1) Can high-grade B-cell-lymphomas be rejected when a foreign antigen is 
expressed? And if yes:  
2) What is the role of the interferon system in the rejection of such lymphomas?  
3) What are the mechanisms of rejection of high-grade B-cell lymphomas? 
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2. Materials and Methods 
Materials 
2.1 Surgical related reagents and equipment 
Formalin: 10% solution of formaldehyde (Sigma-Aldrich) in water. 
Sterile syringes: BD Plastipak 1 ml syringe (BD Biosciences).  
Sterile needles: 0.5 x 25 mm for injection of cell in mice i.v. and 0.55 x 25 mm (BD 
Microlance).  
Erythrocyte lysis buffer: 0.8% NH4Cl with 0.1 mM EDTA (Stem Cell Technologies) 
Heparinized capillaries: (Microvette CB 300) plastic capillaries for collection of blood. 
2.2 Mammalian cell lines 
Phoenix: A packaging cell line expressing gag, pol, and env viral proteins (a kind gift from 
Clemens Schmitt, Humboldt University, Berlin).  
2.3 Oligonucleotides 
All nucleotides were synthesized by Metabion AG, Martinsried. 
Oligonucleotide Sequence 5´ to 3´ 
Ova-XhoI    5´-GCG TCT CGA GGC CAC CAT GGG CTC CAT CGG CG 3´ 
Ova-EcoRI 5´-GAG TGG AAT TCT TAA GGG GAA ACA CAT CTG CC 3´ 
2.4 Plasmids 
MSCV-IRES-GFP: A modified form of the MSCV vector, it contains a bi-cistronic GFP 
expression cassette with an internal ribosomal entry site. 
pcDNA-Chicken Ovalbumin: Vector encoding for the chicken ovalbumin. 
2.5 Antibodies 
Stain    Company   Clone  Fluorochrome
  
CD19   BD Pharmingen 1D3   PE 
H-2Kb   BD Pharmingen AF6-88.5  PE 
IA-b   BD Pharmingen AF6-120.1  PE 
CD80   BD Pharmingen 16-10A1  PE 
CD86   BD Pharmingen GL-1   PE 
CD54   BD Pharmingen 3E2   PE 
CD3e   BD Pharmingen 145-2C11  PE 
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CD4   BD Pharmingen (L3T4)(RM4-5) FITC/PE 
CD8   BD Pharmingen (Ly-2)(53-6.7) FITC/PE 
Vα2-TCR  BD Pharmigen (B20.1)  PE 
Vβ5-TCR  BD Pharmigen (MR9-4)  FITC 
H-2Kb-SIINFEKL Proimmune   not available  PE 
The control pentamer is not available and not included in experiment. 
2.6 Reagents, media and apparatus 
2.6.1 Molecular biology 
Agarose: Molecular biology tested (Sigma-Aldrich). 
Polybrene: cell culture tested (Sigma-Aldrich). 
Small-scale plasmid preparation: GFX miniprep kit for the isolation of plasmid DNA from 
bacteria (Amersham Biosciences). 
Gel Elution of DNA or DNA cleanup: GFX gel elution and PCR purification kit for DNA 
elution from gels and clean up of PCRs (Amersham Biosciences). 
Western blot: ECL Western blotting analysis system (Amersham Biosciences). 
Molecular weight markers: Nucleic acid size standards, 1 kb ladder, 1 kb plus ladder and 
100 bp ladder (Invitrogen). 
Enzymes: Ligase, calf intestine phosphatase, XhoI, EcoRI from New England Biolabs. 
PCR: Platinum Taq DNA polymerase kit, PCR soft tubes (0.2ml) (Biozym Scientific). 
dNTP mix: 10 mM each of dATP, dTTP, dCTP and dGTP (Invitrogen). 
2.6.2 Cell and tissue culture 
Filtration units: Millex syringe-driven 0.22 µm and 0.45 µm filter units (Millipore). 
Cell strainer: BD Falcon 40 µm nylon strainer for macerating the spleen and filtering the 
tissue (BD Biosciences). 
Cell scrapers: 25 cm sterile cell scrapers (Sarstedt). 
Cell culture pipettes (2, 5, 10 and 25 ml): Sterile disposable pipettes (Corning Inc.). 
Cell culture plates and dishes: Sterile 96 well, 24 well, 6 well plates (Sarstedt) 100 mm x 20 
mm dishes for adherent cells (Corning Inc.), and Petri dishes for suspension cells (Becton 
Dickinson) 150 mm x 20mm dishes for adherent cells (Greiner Bio One). 
Calcium chloride solution for transfection: 2.5 M CaCl2 (Sigma-Aldrich) solution in water. 
Hepes buffered saline: (HBS) (Invitrogen). 
Media: Dulbecco’s Modified Eagle Medium (DMEM) (PAN Biotech). 
Fetal bovine serum (FBS): 0,2 µm-filtered mycoplasma screened (PAN Biotech). 
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Dulbecco’s phosphate buffered saline (DPBS) (PAN Biotech). 
Iscove’s Modified Dulbecco media (IMDM) for lymphoma cell culture (Invitrogen) 
Trypsin – EDTA in 1 x HBS (Invitrogen). 
Penicillin/Streptomycin: Antibiotic solution with 10,000 U/ml Penicillin G sodium and 
10,000µg/ml Streptomycin sulfate in 0,85% saline. Used at a final concentration of 1:100 
(Invitrogen). 
Murine cytokines: m-IFN-α and m-IFN-γ (lyophilized) (BD Biosciences)  
Flow cytometry: BD FACS Calibur System (BD Biosciences). 
Fluorescence activated cell sorting: BD FACSVantage SE System (BD Biosciences). 
Microscope: Leitz Diavert Inverted Microscope (Leitz) 
 
Supplementation of Iscove’s Modified Dulbecco media (IMDM) for lymphoma cell 
culture 
500 ml of IMDM (Invitrogen) 
10% heat inactivated FBS (Invitrogen) 
2 mM L-glutamate (Invitrogen) 
2 mM penicillin-streptomycin (Invitrogen) 
1 mM sodium pyruvate (Invitrogen) 
1 % fungizone (Invitrogen) 
 
Supplementation of Dulbecco’s modified eagle’s media (DMEM) for phoenix cell culture 
500 ml of DMEM-high glucose (Invitrogen) 
10% heat inactivated fetal bovine serum (Invitrogen) 
2 mM L-glutamate (Invitrogen) 
2 mM penicillin-streptomycin (Invitrogen) 
1 mM sodium pyruvate (Invitrogen) 
1 % fungizone (Invitrogen) 
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2.7 Mice 
The different mouse strains used in this study are shown in table 4. 
 
Name Vendor 
 
C57BL/6 
 
UBQ-GFP tg C57BL/6 
 
C57BL/6 λ-hu-c-myc tg 
 
 
Stat1-/- 
 
 
C57BL/6-OT1Tg(TcraTcrb)1100Mjb/J 
 
C57BL/6IFN-γ-/-(C57BL/6.129S7-Ifngtm1Ts/J) 
 
 
Charles River Laboratories 
 
Jackson Laboratories 
 
Gift from HC Morse 
(NIAID,NIH) 
 
From David E Levy 
(Durbin et al., 1996) 
 
Jackson Laboratories 
 
Jackson Laboratories 
 
 
Table 4 Different mouse strains used for the study is shown 
Mice lines used in this study 
C57BL/6 mice are wild-type recipients. Around 8-10 week old mice were used as recipients 
in all our lymphoma transfer experiments. 
 
UBQ-GFP tg C57BL/6 mice is a transgenic mice expressing GFP ubiquitously all over the 
tissues and therefore T cells developed in these mice are tolerant to GFP antigen. Upon 
transfer of lymphomas expressing GFP (291-GFP or 9-GFP), GFP does not act as antigen and 
we can rule out the immune response elicited by GFP antigen by transferring in UBQ-GFP Tg 
recipients and in wild-type recipients.  
 
C57BL/6 λ-hu-c-myc tg mice are transgenic for human c-myc mice lead to the development of 
spontaneous lymphomas six months post birth. Lymphomas with striking similarities to 
Burkitt’s lymphoma are developed in these mice. These mice bear a mutated human c-myc 
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gene controlled by reconstructed Ig λ locus. Lymphomas are established in culture from these 
mice and transferred in both wild-type immunocompetent and immunodeficient mice in our 
studies. 
 
Stat1-/- and IFN-γ-/- mice are deficient in type-I, type II and type II IFN respectively. To 
explore the contribution of IFN signaling, these mice were used as recipients in our transfer 
experiments. 
 
C57BL/6-OT-ITg (TcraTcrb) mice are T cell receptor transgenic mice recognizing SIINFEKL 
epitope of ovalbumin antigen OVA257-264. Adoptive transfer of either naïve or primed antigen 
specific CD8+ T cells is generated from these mice. These mice are generally used to study 
the CD8+ T cell response in anti-tumor immunity. 
 
All experiments were performed according to the guidelines and approval of the local animal 
protection committee (application: 55.2-1-54-2531-8-04 and 209.1/211-2531-8/04, 
Government of Bavaria, Munich, Germany). 
Methods 
2.8 Establishment of cell lines 
The cell lines were established either from the λ-hu-c-myc transgenic mice or from the tumor 
transplanted recipient mice. Mice were sacrificed by CO2 euthanasia when peripheral lymph 
node enlargements were well palpable and 10mm in diameter. The lymph nodes were 
removed and the tissue was minced into a single cell suspension by using 80 µm cell strainers. 
After preparation of the single cell suspensions, the erythrocytes were removed by incubating 
the lymphoma cells in ice cold ammonium chloride lysis buffer for 5 to 10 minutes. After 
incubation with lysis solution, the cells were washed twice with ice cold PBS or with 10% 
IMDM. The establishment of lymphoma cells grown in the absence of any irradiated feeder 
cells was unsuccessful. The cells were initially grown in Iscove’s modified Dulbecco’s 
medium (IMDM) in the presence of irradiated MRC-5 (human pulmonary fibroblast) as 
feeder cells. After 4-8 weeks, the cells grew independently of the feeder layers and aliquots of 
the cells were frozen in 10% DMSO / 90% FCS and stored short-term at -80˚C and 
subsequently in liquid nitrogen.  
Ammonium Chloride lysis buffer 
This solution is used to lyse the red blood cells from peripheral blood, spleen and tumors and 
bone marrow. 
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Ammonium chloride 10 X lysing concentrate solution 
a) NH4Cl (1.5 M)  80 g 
b) KHCO3 (100 nM)  10 g 
c) Na4 EDTA (10 nM) 3.7 g 
d) distilled H20  1000 mL 
1N HCl or 1 M NaOH 
Adjust the pH to the range of 7.2-7.4. Add distilled water to final volume of 1000 mL. 
To prepare the working solution, dilute the concentrate 1: 10 (10 mL concentrate + 90 mL 
distilled water). 
 
2.9 Cloning of chicken ovalbumin 
 
Figure 4 
Map of MSCV-GFP and MSCV-OVA-GFP retroviral vector 
A 1.1 kb ovalbumin cDNA fragment covering the coding sequence of the gene was amplified 
by PCR using pcDNA3 as template (a kind gift from Prof. Thomas Brocker, Institute of 
Immunology, LMU, Munich). The PCR fragment was digested with EcoRI and XhoI and 
ligated into the EcoRI and XhoI digested murine stem cell virus vector (MSCV) 5 ́ of the 
internal ribosome entry site (IRES) and the enhanced GFP fluorescent protein gene. After 
ligation, competent bacteria were transformed with the ligation products and plated on agar 
plates containing ampicillin as selection marker. Single bacterial colonies were used to 
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inoculate liquid bacterial cultures and the contained plasmids analyzed by restriction enzyme 
digestion. The maps of the plasmids are shown in figure 4. 
  
2.10 Retroviral production and transduction 
Phoenix cells (a kind gift from Prof. Thomas Brocker, Ludwig-Maximilians-University, 
Munich), an ecotrophic packaging cell line for retroviral production, were cultured in 
Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% fetal calf serum 
(FCS) and antibiotics. The components for complete DMEM are described later in this 
chapter. In order to achieve high titer virus, phoenix cells were plated 12 hours before 
transfection at a density of 5 million cells in a 10 cm cell culture dish. Immediately before 
transfection, the media was removed and replenished with media supplemented with 25 µM 
chloroquine. The transfection mix was prepared by mixing 60 µg of plasmid DNA, 75 µl of 
1.5 M CaCl2 and water to a final volume of 750 µl. After adding 750 µl of 2X HBS buffer, the 
mixture was kept at room temperature for 15 minutes and then added at the sides of the 
culture dish. The plates were incubated for 6 hours at 37 º C, then the media was removed and 
the cells were washed twice with PBS before addition of IMDM media. 48 hours later, the 
retroviral supernatants were collected and passed through a 0.45 µm filter. The retroviral 
supernatants were either snap frozen and stored at -80 º C or used immediately for the 
transduction. One million primary lymphoma cells were incubated with 3 ml of retroviral 
supernatants supplemented with 4 µg/ml of polybrene (Sigma) in a 6 well plate and the plates 
were centrifuged at 1200 rpm for 60 minutes at 32 º C. The infected cells were kept at 37 º C 
in an incubator for additional 12 hours. After two cycles of infection, the cells were washed 
with PBS and supplemented with IMDM media. In order to determine the efficiency of 
retroviral transduction, GFP expression was assessed by FACS. 
After the retroviral transduction using either GFP or OVA-GFP, the transduced cells were 
analszed for GFP expression. We obtained initial transduction efficiency of about 10 to 15 %. 
However, we sorted the high GFP populations and after the first round of sorting we could 
increase the GFP populations to about 60 %. After 1 to 2 week, a second sorting was 
performed to enrich the GFP positive lymphomas. We found that after sorting the high GFP 
expressing cells, we could maintain around 95 % of GFP in primary lymphomas after 
retroviral transduction. 
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2.11 Western blotting 
For whole cell lysate preparation, cells were lysed in LCW lysis buffer, containing protease 
inhibitor cocktail (Roche Diagnostics) and incubated for 15 minutes on ice. The cell debris 
was removed by centrifugation for 15 minutes at 4 º C at 10,000 g. The protein concentration 
of the supernantant was determined by the DC protein assay (Bio-Rad), according to the 
manufacturer’s instructions. Equal amount of protein lysates were mixed with sample loading 
buffer, boiled for 5 minutes at 95 º C, and the proteins were separated by 12 % SDS-PAGE at 
160 V in a mini-Protean 3 electrophoresis cell. Proteins were transferred from the gel onto a 
Hybond-C super nitrocellulose membrane in blotting buffer with a trans-blot semi-dry blotter 
at 20 V for 30 minutes. Membranes were blocked with 5 % skim milk powder in TBST for 60 
minutes and hybridized with a primary antibody at 4 º C for atleast 12 hours. Membranes 
were washed three times in TBST for 5 minutes, following HRP-conjugated secondary 
antibody incubation for 90 minutes. The nitrocellulose membrane was repeatedly washed in 
TBST (3 X 5 minutes) and proteins were visualized by ECL detection on hyperfilm. Efficient 
stripping of Hybond-C super membranes was performed with 0.4 M NaOH for 10 minutes.  
Blotting buffer: 10 % Running buffer (10 X), 20% methanol.  
Western analysis of MYC protein expression was performed using a polyclonal antibody (c-
Myc (A-14)-G: sc-789-G; Santa Cruz Biotechnology.  
 
Sample loading buffer (2 X): 100 nM Tris, 4 % SDS, 20 % glycerol, 0.1 % bromophenol 
blue, 100 mM DTT, pH 6.8 
LCW lysis buffer: 0.5 % Triton X-100, 0.5 % sodium deoxycholate salt, 150 mM Nacl, 20 
mM TRIS, 10 mM EDTA, 30 mM Na-Pyrophosphate, pH 7.5 
Running buffer (10 X): 250 mM TRIS-Base, 1 % SDS, 2.5 M glycine 
TBST: 25 mM TRIS, 125 mM NaCl, 0.1 % Tween-20, pH 8.0 
Ponceau Stain: 
Following transfer to nitrocellulose, the membrane was quickly placed in the ponceau stain 
and was shaken in a roller for approximately 5 to 10 minutes. Later, the membrane was 
transferred into Ponceau destain solution and was shaken until the bands are visible. 
1 X Ponceau stain 
0.1 % Ponceau S – 0.5 g Ponceau-S 
1 % acetic acid 5ml acetic acid and made upto 500 ml 
Ponceau Destain 
1 % acetic acid 
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2.12 Tumor transfer and monitoring 
For lymphoma transfer experiments, 8-10 week old mice were used for experiments. 
Preliminary experiments for the cell number for tumor cells injected indicated that 100,000 
cells resulted in tumor formation in 100% of animals. Therefore, using 100,000 cells as lethal 
dose LD100 for lymphoma transfer experiments, we performed the transfer experiments in 
both immunocompetent and immunodeficient recipient mice. 100,000 cells from cultured 
lymphomas were freshly split 48 hours prior to transfer. Cells were washed in cold PBS and 
injected s.c. at the site of the upper flank of the recipient mice. Lymphoma growth was 
measured at the site of injection at least 3 times per week using calipers. The animals were 
killed when the tumor burden became excessive to avoid pain and suffering. The animals 
were regarded as tumor free when surviving for longer than 100 days. 
2.13 Immunization protocol and transfer of naïve and activated OT-I CD8+ T 
cells 
To generate the activated SIINFEKL-specific CD8+ T cells, OT-I mice were immunized with 
5 to 10 million irradiated (20 Gy) 291-OVA-GFP lymphoma cells. The 291-OVA-GFP 
lymphoma cells were injected subcutaneously in C57BL/6 OT-I Tg animals and one week 
later, the mice were boosted with same dose of irradiated 291-OVA-GFP. Two weeks follwed 
by the immunization with irradiated OVA cells leads to the activation of CD8+ SIINFEKL-
specific T cells in OT-I transgenic mice. The transfer of unvaccinated naïve OT-I CD8+ T 
cells served as controls. Naïve or primed OT-I CD8+ T cells were injected in Stat1-/- 
recipients at day 1. We used three cell dose ranging from 0.1 million, 1.0 million and 10 
million OT-I CD8+ T cells were transferred in Stat1-/- recipients at day 1. The 291-OVA-GFP 
lymphoma cells were challenged at day 0 in all groups. Lymphoma group without OT-I CD8 
T cells were also included as control groups. The persistence of naïve and primed transferred 
OT-I CD8+ T cells were evaluated in Stat1-/- recipients by TCR staining using Vα2 and Vβ5.  
2.14 SIINFEKL pentamer staining 
Single cell suspensions from the spleens of diseased 291-GFP and 291-OVA-GFP challenged 
mice were stained for the presence of SIINFEKL-specific CD8+ T cells. One million spleen 
cells were washed twice with wash buffer (0.1% sodium azide, 0.1% BSA in PBS) and 
subsequently resuspended in the residual volume of about 50 µl. The concentration of the 
pentamer was not supplied by the manufacturer. According to the instructions from 
manufacturer, 10 µl of pentamer was used for each staining condition.The fluorescently 
labeled pentamer (Proimmune) was spun down for 5 minutes at 14000 rpm prior to use. One 
million splenocytes were incubated at room temperature with 10 µl pentamer in 50 µl total 
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volume for 15 minutes in the dark. The cells were washed once with wash buffer and 
incubated on ice for 30 minutes following addition of titrated amounts of anti-CD8 antibody. 
Cells were washed twice in wash buffer and analyzed by flow cytometry. 
2.15 Flow cytometric analysis 
Surface expression levels of various CD markers including CD4, CD8 and TCR staining on T 
cells and MHC class I, MHC class II, co-stimulatory molecules on tumor cells was performed 
by flow cytometry. First, around 0.5 million to 1.0 million lymphoma cells or the T cells were 
incubated with blocking antibody 2.4 G2 in a reaction volume of 50 µl for 30 minutes on ice 
to block Fc receptors. All staining of using fluorchrome labeled monoclonal antibodies were 
used according to the manufacturer’s instructions. After blocking the Fc recptors, the FITC 
labeled or PE-labelled mAb was added to the reaction mixture. Generally 1:100 dilution of 
antibody was used for all CD markers. After 30 minutes incubation on ice, the cells were 
washed with 10 % FCS supplemented in PBS. After washing step, the supernantants were 
discarded and the pellet was resuspended in 400 µl PBS supplemented with 10% FCS. The 
dead cells were excluded from the measurement using propidium iodide staining. Flow 
cytometry analysis was performed on a FACScan using CellQuest (BD Biosciences). The 
stained cells were analyzed and the data were processed by CellQuest program. 
2.16 CFSE staining 
The proliferation of the C57BL/6 Eλ-hu-c-Myc-Stat1+/+ and C57BL/6 Eλ-hu-c-Myc-Stat1-/- 
lymphoma cells and the proliferation of the adoptively transferred OT-I T cells was measured 
by labeling the cells with CFSE. A 5mM stock solution of CFSE in PBS was prepared. In 
general, the cells were washed with PBS, centrifuged, and the supernatant aspirated. Working 
concentration of about 2 µM CFSE concentration was prepared by diluting CFSE in 
phosphate buffered saline buffer. About 5 million to 10 million T cell were resuspended in 
prewarmed PBS containing CFSE and incubated at room temperature for 15 minutes. Cells 
were washed in PBS, resuspended in fresh prewarmed medium and incubated for another 30 
minutes to ensure complete CFSE labeling. The CFSE labeled cells were then analyzed by 
FACS. 
2.16 LDH cytotoxicity assay 
The cytotoxicity of effector immune cells was measured using the non-radioactive LDH 
(lactate dehydrogenase) release assay (Clontech). The LDH cytotoxicity detection kit provides 
a simple and precise colorimetric method to measure LDH release. In principle, the LDH is a 
stable cytoplasmic enzyme present in all cells and released upon cell death. 25,000 lymphoma 
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cells were taken as target cells. Different effector to target (E:T) ratios ranging from 0,1:1; to 
10;1 were used in these experiments. The purified populations of Effector cells (either NK 
cells or T cells) were carried out according to the manufacturer’s instruction. The effector and 
target cells were incubated for 8 hrs in a reaction volume of 200 µl and after incubation, 100 
µl of the supernatant was transferred into new 96-well plate and then 100 µl of reaction mix 
consisting of catalyst and dye solution was added to the supernatant and incubated for 30 
minutes at room temperature in the dark. The lymphoma cells with medium were taken to 
calculate the minimal release, and lymphoma cells in the presence of 5 % Triton X-100 for 
maximal release. After incubation, the absorbance at 492 nm wavelength was measured in an 
ELISA reader (Tecan). The percentage of cell-mediated cytotoxicity was calculated as 
follows. 
 
 (effector:test  – minimal release) 
Cytotoxicity (%) =        * 100 
(maximal release – minimal release) 
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3. Results 
We aimed to establish primary lymphoma cells from λ-hu-c-myc transgenic mice in culture. 
Because lymphoma cells often fail to grow ex vivo on their own, they were initially grown for 
4-6 weeks on irradiated human pulmonary fibroblast (MRC-5). Cultivated lymphoma cells 
grew independently of feeder cells after 4-6 weeks and showed high apoptosis rates as 
observed in forward scatter/side scatter profiles in flow cytometry (data not shown). All cells 
showed CD19 positivity confirming the B cell origin of the tumors. The lymphoma cells were 
cultivated in complete 10 % complete Iscove’s Modified Dulbecco Media (IMDM).  
3.1 Determination of lethal dose for lymphoma transfer 
 In preliminary experiments we conducted dose escalation studies of cells inoculated 
subcutaneously (s.c.) to determine the LD100 (lethal dose) of the cell line used. The lowest 
number of 291 cells to reach LD100 was 0.1 million. The implanted lymphoma cells grow at 
the site of injection and growth could be monitored using a caliper. We almost always 
observed systemic growth in lymph nodes and spleen after s.c. injection. We selected the cell 
line 291 for transfer experiments because of the following reasons. As shown in Figure 5, the 
cell line 291 expresses high amounts of c-MYC in comparison to other established lymphoma 
cells. Moreover we found that MHC class I (H-2Kb) expression was low and MHC class II 
(IAb) expression was negative when compared to other lymphoma cell lines established in 
culture (data not shown).  
lane 1        lane 2          lane 3          lane 4          lane 5
anti-human
c-myc Blot
Ponceau stain
 
 Figure 5 
 Western blot of human c-MYC expression in primary lymphoma cells 
The expression of human c-myc was evaluated in 5 different lymphoma cells established in culture. 
Line 291 (lane 4) expressed higher c-myc levels compared to other tested lymphoma cells. Lane 1 = 
line 265; lane 2 = line 288; lane 3 = line 58; lane 4 = 291; lane 5 =307. 20 µg of protein was loaded in 
each lane.  Western analysis of MYC protein expression was performed using a polyclonal antibody c-
Myc (A-14)-G.  Equal loading of proteins was detected by Ponceau stain. The equal protein loading of 
corresponding c-myc band is shown by ponceau stain 
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3.2 Introduction of foreign antigens and establishment of stable cell lines of λ-
hu-c-myc lymphoma cells 
We hypothesized that tumor progression of c-myc induced lymphomas could be due to the 
lack of expression of a strong lymphoma specific antigen. Therefore we sought to introduce 
chicken ovalbumin to the primary lymphomas by retroviral transduction. We choose chicken 
ovalbumin as a foreign antigen because of the following reasons: 
• Chicken ovalbumin is a well characterized T cell antigen. 
• TCR transgenic adoptive transfer approaches are feasible because of the availability of 
OT-I and OT-II TCR transgenic mice on C57BL/6 background. 
• Fluorescent MHC class I pentamers allow the enumeration of antigen-specific CD8+ 
T lymphocytes because the multimeric MHC-peptide complexes bind to T cell 
receptors (TCRs) of a particular specificity. 
• Vaccination with low dose of OVA derived MHC class I binding peptide SIINFEKL 
can result in activation of CD8+ effector T cells.   
 
In order to establish stable cell lines from 291 cells expressing foreign antigens we used 
retroviral transduction. High GFP expressing cells were sorted by flow cytometry and 
approximately 95% purity was achieved. In the retroviral system, GFP in the vector is linked 
via an IRES site and expression of GFP is coupled to the expression of OVA. Thus GFP 
expression in flow cytometry was used as a read out system for antigen expression. The 
expression of GFP after sorting remained identical over time in culture. In order to rule out 
the possibilities of differences in expression of H-2Kb and IAb molecules after retroviral 
infection, the cell lines were analyzed for the B cell specific marker CD19, H2Kb and IAb 
molecules. As shown in figure 6, the expression of H-2Kb and IAb remained unaltered in 291-
non transduced (291-Parental cells), 291-GFP (Mock virus infected) and in 291-OVA-GFP 
cell lines (Ovalbumin virus infected). 
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Figure 6 
Expression of CD19, H-2Kb and IAb is not altered after retroviral transduction of lymphoma cell 
line 291  
Chicken ovalbumin was introduced into the 291 cell line by retroviral transduction. The unmanipulated 
291 parental cells, 291-GFP cells and 291-OVA-GFP cells after retroviral transduction were analyzed 
for GFP expression, CD19, H-2Kb and IAb surface expression. The H-2Kb and IAb expression was 
determined on CD19 positive cells. The retroviral transduction did not alter the surface expression of 
H-2Kb and IAb molecules. The CD19, H-2Kb and IAb expression of 291 cells was compared with cells 
isolated ex vivo from lymph nodes (LN) of wild-type C57BL/6 mice. 
3.3 Introduction of OVA into 291 lymphoma cells leads to delay in tumor 
formation 
The parental 291 cell line exhibits one possible foreign antigen, the human c-myc gene 
product. When transduced with GFP containing mock vector, GFP will only serve as an 
antigen when transferred into C57BL/6 mice but not into UBQ-GFP-C57BL/6 mice. 
Similarly, 291-OVA-GFP transduced cells exhibit 3 possible antigens namely MYC, GFP and 
OVA, when transferred into C57BL/6 mice, and two antigens when transferred into UBQ-
GFP-C57BL/6 mice. Because transfer of 100,000 cells resulted in 100% mortality, human 
MYC expression alone does not induce antitumor immunity in this experimental setting. With 
the transduction using OVA-GFP containing vector, we introduced 2 new foreign antigens 
into 291 lymphoma cells, GFP and ovalbumin, respectively. This model for lymphoma 
transfer was chosen such that we can eliminate GFP as antigen by transferring transduced 
cells into GFP transgenic mice which are tolerant towards GFP. We therefore can use the 
system to explore the rejection mediated by introduction of GFP and OVA, or OVA antigen 
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alone. Table 5 displays the different antigens upon transfer of cell line 291 into C57BL/6 and 
UBQ-GFP C57BL/6 mice in our lymphoma transfer model. 
 
 
 
 
Table 5 Foreign antigens in 291 cell lines 
Foreign antigens expressed in 291 parental cells, 291-GFP and 291-OVA-GFP lymphoma cell lines 
when transferred in both wild-type C57BL/6 recipients and in UBQ-GFP-transgenic recipients. Since 
the GFP is expressed ubiquitously in UBQ-GFP-Tg mice, GFP does not act as antigen upon transfer 
of GFP expressing lymphomas in these recipients. 
 
To test the in vivo efficiency of OVA-mediated rejection, 291 parental cells, 291-GFP and 
291-OVA-GFP cells were injected subcutaneously into immunocompetent wild-type-
C57BL/6 and UBQ-GFP transgenic C57BL/6 mice. As determined in chapter 3.1, we injected 
100,000 cells and the tumor size following lymphoma injection was monitored 3 times a 
week. As shown in figure 7, parental lymphoma bearing animals developed lymphoma at day 
16 and tumor grew progressively over time. This observation is consistent in both wild-type-
C57BL/6 and UBQ-GFP transgenic animals as recipients. When 291-GFP cells were injected 
into wild-type C57BL/6 animals, we observed a delay of lymphoma onset of approximately 4-
5 days compared to UBQ-GFP recipients which are tolerant to GFP. 291-GFP cells grew as 
fast in UBQ-GFP transgenic mice as 291 parental cells. This suggests that introduction of 
GFP into lymphoma cells elicits detectable anti-tumoral activity. Most interestingly, there was 
a consistent delay in lymphoma growth in case of 291-OVA-GFP cells in both wild-type 
C57BL/6 and UBQ-GFP transgenic animals indicating that ovalbumin response mediated the 
delay in tumor development. The 291-OVA-GFP cells developed lymphoma at day 26 with 
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MYC 
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MYC 
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291- OVA-GFP 
MYC 
 
MYC
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291- GFP  
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291 Parental Line 
(Non transduced) 
UBQ-GFP-Tg  
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significant delay of 10 days when compared with 291 parental cells in wild-type C57BL/6 
mice and 291-GFP cells in UBQ-GFP transgenic animals. Although there was delay in tumor 
development in case of 291-OVA-GFP lymphomas, 291-OVA-GFP lymphomas grew 
progressively in some WT-C57BL/6 and UBQ-GFP transgenic animals. 
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 Figure 7 
 Introduction of ovalbumin delays lymphoma growth in wild-type C57BL/6 and C57BL/6 UBQ-
GFP transgenic recipients 
100,000 cells each for 291 Parental cells, 291-GFP, and 291-OVA-GFP cells were injected s.c. in both 
wild-type C57BL/6 and UBQ-GFP transgenic mice. Upon lymphoma progression, tumor size at the site 
of injection was measured 3 times per week using calipers. The 291 parental cells grew progressively 
in both wild type (A) and UBQ-GFP transgenic (B) recipients, whereas the 291-OVA-GFP lymphomas 
display 10 days delay in lymphoma growth. The immune response against ovalbumin bearing 
lymphoma is not due to the presence of GFP antigen, as 291-GFP cells grew progressively in UBQ-
GFP transgenic recipients. The graph shows combined data from four independent experiments with 
similar results. The lymphoma growth of 291 parental cells is shown in black, that of 291-GFP cells in 
green, and that of 291-OVA-GFP cells in red. 
 46
 
 
Figure 8 
Overall survival of recipient mice is increased when challenged with a tumor expressing a 
foreign antigen  
The immune response against ovalbumin bearing lymphomas were monitored for long term survivors 
after tumor challenge. All the mice challenged with 291 parental cells grew progressively and killed the 
mice within 20 days after challenge in both wild-type C57BL/6 (A) and in UBQ-GFP transgenic (B) 
recipients (black line). In contrast, introduction of OVA-GFP led to improved survival in both recipient 
strains (291-OVA-GFP cells) (red line). Around 45% of animals challenged with 291-OVA-GFP 
survived for more than 100 days without any signs of lymphoma. The introduction of GFP displayed 
protection only in wild-type animals (291-GFP cells) (green line) leading to long term survival for more 
than 100 days. All the animals challenged with 291-GFP developed tumors and killed the mice within 
20 days in GFP tg recipients.  
 
Corresponding to the delay in lymphoma growth, 40-45 % of the animals rejected lymphoma 
cells completely when the OVA-GFP had been introduced into the cells. As shown in figure 
8, all animals harboring unmanipulated 291 parental cells (black line) died because of 
progressive lymphoma. Comparable results were observed in wild-type C57BL/6 and UBQ-
GFP transgenic mice. By contrast, 40-45 % of the animals inoculated with lymphoma cells 
harbouring 291-OVA-GFP (red line) rejected the lymphoma cells and remained tumor free 
after 100 days without any signs of lymphoma. Similar results were observed when UBQ-
GFP transgenic mice were used as recipients for 291 parental and OVA-GFP transduced cells. 
However, when the cells had been transduced with GFP only, survival of 291-GFP lymphoma 
bearing animals in wild-type C57BL/6 animals was nearly identical to that of wild-type 
C57BL/6 animals receiving 291-OVA-GFP lymphoma cells, and 40 % of the animals 
remained tumor free after 100 days without any sign of lymphoma. This effect was not 
291 Parental cells (n=15)
291-GFP cells (n=15)
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observed in GFP-transgenic mice. This data clearly indicates that GFP acts as an antigen and 
increases the immunogenicity of lymphomas.  
3.4 Loss of antigen in outgrowing lymphomas 
As shown in the figure 8, approximately 60 % of the recipient animals developed lymphoma 
despite the presence of OVA. We therefore analyzed outgrowing tumors for their expression 
of GFP as a surrogate marker for antigen expression. As shown in the figure 6, we obtained 
approximately 95 % purity of GFP expressing cells after FACS sorting and addressed the 
question whether outgrowing lymphomas were selected for loss of antigen. The GFP 
expression of the 291-GFP and 291-OVA-GFP cell lines was determined prior to injection 
and compared to the GFP expression on lymphomas arising in wild-type C57BL/6 and UBQ-
GFP transgenic mice. When the tumor burden was critical (above 10 mm), outgrowing 
lymphomas were harvested and subsequently analyzed for GFP expression by flow 
cytometry. As shown in figure 9, we observed partial loss of GFP expression in wild-type 
recipient mice challenged with 291-GFP cells. Striking differences emerged when GFP 
expression was compared in developing tumors in wild-type C57BL/6 and UBQ-GFP 
transgenic mice. Ex vivo analysis of GFP expression confirmed that 291-GFP lymphomas 
arising in GFP transgenic mice display high GFP expression as shown in figure 9. However, 
expression of GFP was dramatically reduced in lymphomas transduced with OVA-GFP that 
were arising in wild type C57BL/6 (A) and in UBQ-GFP transgenic mice (B). We conclude 
that introduction of ovalbumin delays the tumor formation, and developing lymphoma 
displays a loss of antigen.  
 
However, differences emerged when the GFP expression of 291-OVA-GFP lymphomas 
arising in wild type C57BL/6 and UBQ-GFP transgenic mice was investigated. The GFP 
expression of developing 291-OVA-GFP lymphomas in wild type C57BL/6 displayed 25 % 
compared with the 35 % for 291-OVA-GFP lymphomas developing in C57BL/6 UBQ-GFP 
transgenic mice. Thus from this experiment, we conclude that introduction of ovalbumin 
delays the tumor formation and, developing lymphoma display a loss of antigen. 
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 Figure 9 
 Loss of antigen in lymphomas developing in recipient wild-type and UBQ-GFP transgenic mice 
after inoculation of 291 cells transduced with GFP or OVA-GFP  
After the challenge of 100,000 cells of 291-GFP and 291-OVA-GFP,GFP expression of 291-GFP and 
291-OVA-GFP cells was compared after injection into C57BL/6 wild type (A) and C57BL/6 UBQ-GFP 
transgenic mice (B). Since GFP antigen is tolerant in UBQ-GFP-Tg mice, we observed almost 90% of 
GFP expression in developing lymphomas after challenge with 291-GFP indicating no loss of antigen 
variants. However, 25 % of GFP expression is observed in developing 291-OVA-GFP lymphomas in 
wild-type recipients and 35% of GFP expression is observed in developing 291-OVA-GFP lymphomas 
in UBQ-GFP Tg recipients indicating emergence of loss of antigen variants after 291-OVA-GFP 
challenge. Graphs display the % mean fluorescence intensity of GFP expression of injected cells. 
P<0.05 in wild-type C57BL/6 recipients and P=0.01in UBQ-GFP transgenic recipients. n=8 for 291-
GFP and 291-OVA-GFP cells in both wild-type C57BL/6 and UBQ-GFP-Tg recipients. 
 
3.5 Detection of SIINFEKL specific T cells in splenocytes of mice that have 
rejected lymphoma cells expressing ovalbumin and GFP 
As shown in the figure 8, 40-45 % of the recipient animals rejected OVA bearing lymphomas. 
We hypothesized that elicitation of an ovalbumin specific immune response led to the 
rejection of 291-OVA-GFP lymphoma cells. The analysis of an antigen-specific CD8+ T cell 
response has been greatly facilitated by the recent introduction of tetramer/pentamer 
technology that allows accurate enumeration and phenotypic characterization of antigen 
specific T cells by flow cytometry. With available SIINFEKL-specific pentamers, we 
determined the presence of antigen-specific CD8+ T cells in mice during ovalbumin mediated 
lymphoma rejection. As shown in the figure 10, the animals injected with 291-GFP cells 
displayed background staining of about 0.3 %, whereas the splenocytes of 291-OVA-GFP 
challenged animals displayed around 1,6 % of SIINFEKL-specific CD8 T cells. We conclude 
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from this experiment that inoculation of mice with ovalbumin expressing lymphoma cells 
leads to the generation of SIINFEKL-specific CD8+ T cells which could eventually mediate 
rejection. 
 
 Figure 10 
 Detection of SIINFEKL-specific CD8+ T cells in splenocytes of wild-type mice that have 
rejected ovalbumin-GFP expressing lymphoma cells  
The percentage of SIINFEKL- pentamer positive T cells in splenocytes of wild type C57BL/6 mice that 
have received either 100,000 cells of 291-GFP or 291-OVA-GFP cells was determined by flow 
cytometry. Rejected mice after challenge of 291-GFP and 291-OVA-GFP at day 40 was sacrificed and 
splenocytes was analyzed for the presence of SIINFEKL positive cells. Graphs display the pentamer 
positive cells ± standard deviation by Mann-Whitney non-parametric test. P=0.008 compared to the 
control group.n=6 for 291-GFP and 291-OVA-GFP. 
3.6 Stat1 and IFN-γ deficient mice fail to reject OVA-GFP cells 
We have shown that expression of the foreign antigen OVA in lymphoma cells enhanced the 
immunogenicity of the cells and resulted in partial rejection and selection of antigen loss 
variants. To investigate whether rejection requires the endogeneous production of IFN-γ by 
the host, we transferred the immunogenic 291-OVA-GFP cells in IFN-γ-/- recipients. As 
described in chapter 1.5, Stat1 is instrumental for the biological actions of both type I and 
type II interferons. Therefore, Stat1 deficient mice were also employed as tumor recipients. 
As control, we transferred the 291-OVA-GFP cells in wild-type C57BL/6 mice. As shown in 
Figure 11, the 291-OVA-GFP cells start to develop palpable tumors at day 22 in IFN-γ-/- mice 
in comparison with lymphoma development at day 26 in wild type control recipients. Striking 
differences emerged when 291-OVA-GFP cells were transferred in syngeneic Stat1-/- 
recipients. As shown in figure 11, the 291-OVA-GFP cells begin to develop lymphoma at day 
10 in Stat1-/- recipients.  
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Figure 11  
Accelerated tumor growth (A) and decreased overall survival (B) of Stat1-/- and IFNγ-/- recipient 
mice challenged with OVA-GFP expressing lymphoma cells 
0.1 million cell dose of 291-OVA-GFP lymphoma were transferred in WT-C57BL/6 (solid red line), 
Stat1-/- (dashed black line) and IFN-γ-/- recipients (dashed light brown line). (A) Tumor growth was 
assessed 3 times/week using calipers and is depicted as mean +/- S.D. (B) Kaplan-Meier plots 
showing overall survival of different recipients after challenge with 291-OVA-GFP cells. 291-OVA-GFP 
cells develop lymphoma at day 26, day 10 and day 22 in wild-type, Stat1-/- and IFN-γ -/- recipients 
respectively. 65% of animals survived for long term after 291-OVA-GFP challenge in wild-type 
recipients whereas 93% of IFN-γ -/- and Stat1-/- recipients died because of tumor development. 
P value was calculated using log rank test for survival. P < 0.01 for all groups. 
 
The differences among the recipients with different genetic background became much more 
obvious when the overall survival was analyzed instead of tumor growth. As shown in figure 
11, the growth kinetics and tumor size was also reflected when survival was analyzed. Stat1-/- 
recipients displayed a significantly faster lymphoma growth compared to IFN-γ-/- or C57BL/6 
recipients and approximately 93 % of the animals died due to lymphoma progression. In 
contrast, tumor growth kinetics of IFN-γ-/- host were comparable to C57BL/6 mice. However, 
most interestingly the difference was reflected by survival since 90 % of the IFN-γ-/- 
recipients died of progressive lymphoma whereas 65 % of C57BL/6 mice successively 
rejected 291-OVA-GFP lymphomas and survived long term. 
The IFN-γ-/- mice develop lymphomas at the same kinetics compared to lymphoma 
development in C57BL/6 mice. By contrast, Stat1-/- display much faster tumor growth and fail 
to reject 291-OVA-GFP lymphomas. This could give us the hint for the early involvement of 
NK cells in tumor rejection, since Stat1-/- mice exhibit defects in NK function. Thus from this 
experiment, it is evident that rejection of ovalbumin transduced lymphoma requires host 
interferon gamma production and Stat1 signaling within the host. 
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3.7 Organ infiltration by 291-OVA-GFP cells is higher in Stat1 and IFN-γ 
deficient mice 
Since we found that 291-OVA-GFP cells grew progressively in IFN-γ and Stat1 deficient 
mice, we sought to determine the mechanism behind tumor progression. The tumor 
infiltration of 291-OVA-GFP cells within different organs of IFN-γ-/- , Stat1-/- and wild-type 
C57BL/6 recipients was determined by GFP fluorescence staining. As shown in figure 12, we 
detected increased tumor infiltration in the spleen of tumor bearing animals in IFN-γ-/- and 
Stat1-/- recipients and most importantly, the tumor did not infiltrate the spleen of wild-type 
recipients. Thus the experiment indicates that the failure to reject 291-OVA-GFP cells by 
IFN-γ-/- and Stat1-/- recipients was due to increased infiltration of tumors in their spleens 
indicating escape from immunological recognition. 
 
 
Figure 12  
IFN-γ-/- and Stat1-/- recipient mice showed increased splenic infiltration with 291-OVA-GFP cells 
as compared to wild-type recipients 
Wild-type, Stat1-/- and IFN-γ-/- recipients were challenged with 100,000 cells of 291-OVA-GFP .Splenic 
infiltration by 291-OVA-GFP cells in IFN-γ-/-, Stat1-/- and in wild-type C57BL/6 mice is analyzed. When 
the tumor burden is huge and when the animals suffer, the animals were killed at day 28 and the 
tumor infiltration was evaluated by the presence of GFP-expressing cells in the spleen of tumor 
bearing animals. The presence of GFP-expressing lymphoma cells were indicated as % cells and 
tumor cells infiltrate at higher numbers in IFN-γ -/- and Stat1-/- recipients but not in wild-type recipients. . 
The analysis shows three animals from each group. 
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3.8 Expression of antigen is preserved in IFN-γ-/- and Stat1-/- mice 
Similarly to the analysis presented in figure 9, we analyzed GFP expression in outgrowing 
291-OVA-GFP lymphomas not only in wild-type C57BL/6, but also in IFN-γ-/- and Stat1-/-
mice. As shown in figure 13, we observed a reduction of GFP-expression in wild-type 
C57BL/6 host as described earlier. In contrast, GFP was expressed at about 10 fold higher 
levels when Stat1-/- mice were used as recipients (p=0.001). Although 90 % of IFN-γ-/- mice 
receiving 291-OVA-GFP cells failed to reject the lymphoma, we observed a significant 
reduction of GFP expression when compared to Stat1-/- recipients (p=0.003). This GFP 
expression in developing lymphomas in IFN-γ-/-was still significantly higher as compared to 
lymphomas from C57BL/6 recipients (p=0.034). This indicates that loss of IFN-γ can partially 
be compensated, presumably by type-I interferons and maintenance of selective pressure. 
Thus from this experiment it is evident that increased lymphoma growth and lack of rejection 
of highly immunogenic 291-OVA-GFP lymphomas in IFN-γ-/- and Stat1-/- mice was not due 
to the loss of antigen as tumor escape mechanism.  
 
 
Figure 13  
Selection for antigen-loss variants in developing lymphomas arising in wild-type, but not in 
IFN-γ-/- and Stat1-/- recipients upon challenge with 291-OVA-GFP cells 
Wild-type, IFN-γ-/- and Stat1-/- recipients were challenged with 100,000 cell dose of 291-OVA-GFP 
lymphoma cells. GFP expression of 291-OVA-GFP cells was compared after injection into wild-type 
(n=8), IFN-γ-/- (n=10) and Stat1-/- (n=10) recipient mice. The animals were killed at day 28 and the 
GFP expression was evaluated in developing lymphomas. The GFP expression of lymphomas from 
Stat1-/- recipients was 3 to 4 fold higher than that of IFN-γ-/- recipients indicating that antigen 
expression is preserved in developing lymphomas from Stat1-/- recipients and IFN-γ -/- recipients. In 
case of wild-type recipients, developing lymphomas are selected for antigen loss variants. P values 
were determined by Mann Whitney test. 
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3.9 IFN-γ-dependent induction of MHC class I and MHC class II  
Successful T-cell mediated rejection by foreign antigens is considered to require several 
features. In particular, the antigen must be processed and presented in the context of MHC. 
Furthermore, the amount of MHC must be sufficient on the surface to induce T-cell response. 
Moreover, IFN-γ mediated immunosurveillance plays an important role in tumor rejection 
(Shankaran et al., 2001). Therefore we sought to determine the possibility of IFN-γ mediated 
immunogenicity in developing 291-OVA-GFP lymphomas in wild-type, IFN-γ-/- and Stat1-/- 
mice. The surface expression of H-2Kb and IAb in the 291-OVA-GFP cell lines was 
determined before injection and compared with developing 291-OVA-GFP lymphomas in 
control wild-type C57BL/6, IFN-γ-/- and Stat1-/- recipients. As shown in figure 14, lymphomas 
developing in C57BL/6 mice exhibited about 3 fold higher H-2Kb and approximately 100 fold 
higher IAb expression than the parental 291-OVA-GFP cells cultivated before inoculation in 
vitro. This induction of H-2Kb and IAb expression was not observed in Stat1-/- and IFN-γ-/- 
recipients and both strains failed to reject the lymphoma. From this experiment, we conclude 
that induction of MHC-class I and class II is associated with lymphoma rejection in our 
experimental system. 
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Figure 14 
MHC expression was upregulated on the cell surface of 291-OVA-GFP lymphoma cells after 
transfer into wild-type mice, but not after transfer into IFNγ-/- and Stat1-/- mice   
H-2Kb and IAb expression of 291-OVA-GFPcells was determined prior to injection and compared to 
that in developing 291-OVA-GFP lymphomas in wildtype, IFN-γ-/- and Stat1-/- recipient mice. The 291-
OVA-GFP bearing lymphomas in wild-type, IFN-γ-/- amd Stat1-/- recipients were analysed at day 30. H-
2Kb expression was induced only in tumors arising in wild-type recipients but not in those arising in 
IFN-γ-/- and Stat1-/- recipients. Similarly, IAb expression was induced only in lymphomas arising in wild-
type C57BL/6 mice and this upregulation was completely abolished in lymphomas arising in IFN-γ-/- 
and Stat1-/- recipients. H-2Kb and IAb expression in cultured 291-OVA-GFP served as controls. n=10 
for IFN-γ-/- and Stat1-/- recipients and n=8 for wild-type recipients.  
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As shown in figure 14, the 291-OVA-GFP lymphomas arising in C57BL/6 animals displayed 
higher H-2Kb and IAb expression levels than the parental 291-OVA-GFP cell line. We wished 
to evaluate the underlying mechanisms and addressed the question whether MHC class I and 
MHC class II upregulation is cell autonomous or requires the in vivo tumor environment. To 
this end, 291-OVA-GFP lymphomas arising in C57BL/6 mice were placed back in culture, 
cultivated for 60 days in vitro, and were then analyzed again for H-2Kb and IAb expression. 
As shown in figure 15, H-2Kb and IAb expression of explanted lymphomas was reduced back 
to basal levels after long term cultivation in vitro. Treatment with murine IFN-γ could 
partially restore MHC expression as shown in figure 15. Treatment with murine IFN-γ led to a 
2-3 fold increase in MHC class I (H-2Kb) and 10 to 15 fold increase in MHC class II 
expression in 291-OVA-GFP lymphomas seeded into culture from C57BL/6 and GFP-
transgenic C57BL/6 recipients.  
Figure 15  
291-OVA-GFP lymphomas arising in wild-type or UBQ-GFP transgenic mice and cultivated ex 
vivo responded to IFN-γ by upregulation of H-2Kb and IAb expression 
291-OVA-GFP lymphomas arising in C57BL/6 and UBQ-GFP transgenic mice were placed back in 
culture and cultivated for two months. The in vitro cultivation led to down regulation of H-2Kb and IAb 
on the cell surface of 291-OVA-GFP lymphoma cells as shown in yellow bars. Treatment of 291-OVA 
cells with murine IFN-γ led to 2-3 fold increase in H-2Kb expression and 10-15 fold increase in IAb 
expression. The expression levels of IFN-γ treated 291-OVA-cells are shown in grey bars. n=5 for both 
untreated cultivated cells and IFN-γ treated cells. 
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3.10 OT-I T cells fail to reject 291-OVA-GFP lymphomas in Stat1-/- recipients 
The previous results demonstrated that Stat1-/- mice provide a platform to allow 291OVA-
GFP cells to grow without loss of antigen indicating no selection pressure as opposed to IFN-
γ-/- mice (Figure 11 and 13). In order to further address rejection mechanisms, we used Stat1-/- 
recipients as host to transfer OT-I CD8+ T cells that harbor an ovalbumin-specific transgenic 
T cell receptor (TCR). CD8+ T cells from OT-I mice express a transgenic TCR that 
recognises H-2Kb and the immunodominant OVA257-264 peptide SIINFEKL. The fast growth 
of 291-OVA-GFP lymphoma in Stat1-/- recipients prompted us to investigate whether 
adoptive transfer of primed OT-I CD8+ T cells is able to mediate tumor rejection. We 
therefore used CD8+ T cells from vaccinated and unvaccinated mice in a dose range from 
10,000 to 1 million CD8+ T cells. C57BL/6 OT-I transgenic mice were vaccinated with 
irradiated 291-OVA-GFP cells one week prior to harvest of CD8+ T cells. The lymphoma 
cells (0.1 million) were injected s.c. at day 0 and the OT-I CD8+ T cells were injected i.v. at 
day 1. As shown in figure 16, neither transfer of naïve OT-I CD8+ T cells, nor of activated 
OT-I CD8+ T cells prevented lymphoma growth, even when the number of activated OT-I T 
cells exceeded the number of lymphoma cells by a factor of 10.  
Figure 16  
OT-I CD8+ T cells failed to reject 291-OVA-GFP cells in Stat1-/- recipients 
The lymphoma cells is injected s.c at day 0 and either naïve or primed OT-I CD8+ T cells is injected i.v 
at day 1. Lymphoma growth after transfer of either naïve or primed OT-I CD8+ T cells following 
inoculation of 291-OVA-GFP cells into Stat1-/- recipients are monitored. Lymphoma growth at the site 
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of injection is measured using calipers. Lymphoma growth was observed in both groups of mice that 
received either naïve or primed OT-I CD-8+ T cells. Two independent experiments were performed 
with identical results. n=10 per group. 
 
The results of this experiment show that OT-I CD8+ T cells fail to reject the lymphoma 
regardless of their priming. Tumor growth was not even delayed after transfer of primed OT-I 
CD8+ T cells despite the fact that the number of OVA-specific T cells was by a factor of 10 
higher in the primed as compared to the unprimed group.  
 
3.11 Primed OT-I T cells persist in tumor bearing Stat1-/- animals 
The failure of naïve or primed OT-I CD8+ T cells to control tumor growth could be due to the 
lack of persistence or expansion post-transfer. The presence of OT-I CD8+ T cells can be 
evaluated by the staining of T cell receptor Vα2 and Vβ5 CD8+ T cells. The TCR staining 
was performed when the recipient mice were bearing tumor size of about 10 mm. As shown in 
figure 17, twenty three days after transfer of the T cells, we could detect large numbers of OT-
I CD8+ T cells only in the group of mice that had received primed OT-I T cells but not the 
group that had received naïve T cells.  
 
Figure 17 
Ovalbumin-specific OT-I CD8+ T cells persisted in Stat1-/- recipients challenged with 291-OVA-
GFP cells 
The persistence of naïve or primed transferred OT-I CD8+ T cells in the spleen of Stat1-/- recipients 
were evaluated by TCR staining for Vα2 and Vβ5. After the tumor challenge and T cell transfer in 
Stat1-/- recipients, all diseased animals were killed and the TCR staining was performed at day 26 in 
the splenocytes of lymphoma bearing animals. The Vβ5-TCR stain is shown in the X- and the Vα2-
TCR stain in the Y-axis. Results are shown from three mice of each group that had received either 
naïve or primed OT-I T cells. Persistence of transferred OT-I CD8+ T cells is shown in quadrant plot 
as % cells positive for both Vα2 and Vβ5. 
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3.12 Generation of IFN unresponsive lymphoma cells 
Since our data so far had demonstrated the importance of MHC upregulation and IFN-γ for 
the rejection of 291-OVA-GFP cells, we hypothesized that unresponsiveness towards IFNs 
would render cells invisible to T-cells and therefore promote tumor growth despite the 
presence of foreign antigen. For the generation of Stat1-deficient lymphoma cells, we 
crossbred λ-hu-c-myc transgenic mice with Stat1-/- animals maintained on C57BL/6 
background. The survival of λ-hu-c-myc transgenic Stat1-/- mice compared to that of λ-hu-c-
myc transgenic mice is shown in figure 18. Loss of Stat1 led to a slight, but significant 
acceleration of tumor development. 
 
Figure 18  
Loss of Stat1 slightly accelerated λ-hu-c-myc-induced lymphoma development in vivo 
C57BL/6 λ-hu-c-myc Tg mice were cross bred with Stat1-/- mice to generate λ-hu-c-myc Tg-Stat1-/- 
mice.  Kaplan-Meier plot of the survival of λ-hu-c-myc Stat1+/+ and λ-hu-c-myc Stat1-/- transgenic mice. 
The median survival of λ-hu-c-myc Stat1+/+ mice was 107 days and that of λ-hu-c-myc Stat1-/- mice 87 
days (P=0.003). Loss of Stat1 within c-myc overexpressing lymphomas accelerated lymphoma 
development compared with Stat1 competent λ-hu-c-myc Tg mice. 
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3.13 Stat1-/- lymphomas are unresponsive to IFN-γ 
After establishing the Stat1-deficient lymphomas in culture, we studied the action of murine 
IFN-γ on Stat1-competent and Stat1-deficient lymphoma cell lines in vitro. As shown in 
figure 19, H-2Kb and IAb upregulation was observed only in Stat1-competent cells (line 291) 
cells, but the effect of murine IFN-γ on MHC class I and class II expression was completely 
abolished in Stat1-deficient lymphoma cells (line 9). It is thus evident from this experiment 
that MHC-upregulation through IFN-γ is indeed dependent on Stat1, as expected. 
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Figure 19  
Stat1-/- lymphomas did not respond to IFN-γ 
Stat1-competent (line 291) and Stat1-deficient cells (line 9) were analyzed for their sensitivity to 
murine IFN-γ. The cells were treated with murine IFN-γ for 48 hours and cell surface expression of H-
2Kb and IAb was determined. H-2Kb and IAb were upregulated in Stat1 competent cells and this effect 
was completely abolished in Stat1 deficient lymphoma cells. 
 
Similarly to the Stat1-competent 291-Stat1+/+ cell line, we introduced chicken ovalbumin and 
GFP into the Stat1 deficient lymphoma cell line (9-Stat1-/-). After retroviral transduction, the 
infected cells were monitored for GFP expression by flow cytometry. In order to establish a 
Stat1-deficient cell line that expresses the foreign antigens, high GFP expressing cells were 
sorted. As shown in figure 20, about 95% of 9-Stat1-/--GFP and 9-Stat1-/--OVA-GFP cells 
expressed GFP. Since we wished to study the immune response against GFP and ovalbumin 
expressing lymphomas, we monitored the stability of foreign antigen expression in lymphoma 
cells in vitro by measuring GFP expression as read out. We found that GFP expression 
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remained virtually unaltered in culture for more than 100 days. In order to rule out differences 
in the expression of MHC molecules after retroviral transduction, the cell lines were analyzed 
for the surface expression of H-2Kb, IAb and CD19 markers. As shown in figure 20, the level 
of H-2Kb, IAb and CD19 expression remained unaltered in 9-Stat1-/--GFP and 9-Stat1-/--OVA-
GFP cells as compared to 9-Stat1-/- parental cells confirming that retroviral transduction 
procedures did not alter the surface phenotype of the cells. 
 
 Figure 20 
 No alteration of CD19, H-2Kb, and IAb expression after retroviral transfer of chicken ovalbumin 
and GFP into 9-Stat1-/- lymphoma cells  
9-Stat1-/- cells were retrovirally transduced and GFP, CD19, H-2Kb and IAb expression in 9-GFP-Stat1-
/-, 9-OVA-GFP-Stat1-/-, and unmanipulated parental 9-Stat1-/- cells monitored by flow cytometry. 
Retroviral transduction did not alter the surface expression of H-2Kb and IAb molecules. Expression of 
CD19, H-2Kb and IAb of 9-Stat1-/- lymphoma cells was compared with that of cells in lymph nodes of 
wild-type C57BL/6 mice.  
 
3.14 Stat1 deficient lymphoma is rejected upon transfer into immuno-
competent mice 
To test the immunological recognition of Stat1-/- tumors, GFP- and OVA-GFP transduced 9-
Stat1-/- lymphoma cells were inoculated into immunocompetent UBQ-GFP transgenic 
C57BL/6 mice. As shown in figure 21, partial lymphoma growth was observed upon transfer 
of 9-GFP-Stat1-/- cells and 9-OVA-GFP-Stat1-/- cells in UBQ-GFP transgenic C57BL/6 
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recipients but growth was discontinuous and the tumor started to regress over time in the 
majority of cases. Corresponding to this discontinuous tumor growth, approximately 85% of 
the animals rejected the lymphoma cells completely, irrespective of the presence of OVA 
antigen. Thus both 9-GFP-Stat1-/- cells and 9-OVA-GFP-Stat1-/- cells were rejected efficiently 
upon transfer into immunocompetent UBQ-GFP transgenic mice. Thus, this experiment 
suggests that loss of Stat1 signaling does not lead to enhanced tumorigenesis as one might 
have expected, it rather leads to efficient rejection independent of the presence of strong 
foreign antigen. The growth kinetics of the tumor and the overall survival of UQB-GFP 
transgenic mice upon challenge with 9-GFP-Stat1-/- and 9-OVA-GFP-Stat1-/- cells are shown 
in figure 21. 
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Figure 21  
Stat1-deficient lymphomas were rejected in UBQ-GFP-transgenic recipients irrespective of 
foreign antigen expression in the tumor 
UBQ-GFP-Tg recipients were challenged with 100,000 cells of 9-GFP-Stat1-/- and 9-OVA-GFP-Stat1-/- 
lymphoma cells. A) 9-GFP-Stat1-/- (green line) and 9-OVA-GFP-Stat1-/- lymphoma cells (red line) were 
injected s.c. in UBQ-GFP transgenic wild-type C57BL/6 recipients and the tumor size at the site of 
injection was measured 3 times a week using calipers. Three independent experiments were 
performed with reproducible results. B) Overall survival of UBQ-GFP mice challenged with Stat1-
deficient lymphoma cells expressing GFP (green) or GFP and OVA (red). Loss of Stat1 by the 
lymphoma cells led to efficient rejection in UBQ-GFP-transgenic recipients irrespective of the 
expression of OVA antigen.  
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3.15 IFN-γ-/- and Stat1-/- recipients fail to reject Stat1 deficient lymphomas  
The rejection of 9-GFP-Stat1-/- and 9-OVA-GFP-Stat1-/- cells in GFP-transgenic 
immunocompetent mice provided evidence for antigen-independent rejection. Since 80-85% 
of GFP-transduced Stat1-deficient lymphomas were rejected in GFP-transgenic mice, we 
investigated the mechanisms involved in the process. Furthermore, we knew already from 
previous experiments that rejection of Stat1 competent, foreign antigen expressing cells (line 
291) requires production of IFN-γ and Stat1 signaling by the host. To address the question 
whether rejection of Stat1-deficient lymphomas also requires host IFN-γ and Stat1, we 
transplanted Stat1-/- lymphoma cells into IFN-γ-/- and Stat1-/- recipients. As rejection of Stat1-
deficient lymphomas was independent of foreign antigen, we used 9-GFP-Stat1-/- cells and 
UBQ-GFP transgenic mice as recipients for further experiments. As shown in figure 22, 
transfer of 9-GFP-Stat1-/- cells into UBQ-GFP transgenic as well as wild-type C57BL/6 mice 
led to efficient rejection. However, striking differences emerged when 9-GFP-Stat1-/- cells 
were transferred into IFN-γ-/- and Stat1-/- recipients. Transfer of 9-GFP-Stat1-/- cells into IFN-
γ-/- and Stat1-/- mice led to early lymphoma onset at day 10 and continuous tumor progression, 
whereas they were rejected in wild-type C57BL/6 mice. The results indicate that lack of IFN 
responsiveness within the lymphoma does not affect induction of an immune response, 
however, lack of IFN-γ and of Stat1 signaling within the host increases tumorigenicity. Thus, 
it is important to note that rejection of both, Stat1 competent cells (line 291) in an antigen-
dependent manner and rejection of Stat1 deficient cells (line 9) in an antigen-independent 
manner requires production of IFN-γ and Stat1 signaling by the host. 
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Figure 22  
Host IFN-γ and Stat1 were required for antigen-independent rejection of Stat1-deficient 
lymphoma cells 
9-GFP-Stat1-/- lymphoma cells were injected s.c. into wild-type (black line), UBQ-GFP transgenic 
(green line), IFN-/- (blue line), and Stat1-/- recipients (red line). 0.1 million cells were injected in each 
recipient mice and the tumor size at the site of injection was measured 3 times a week using calipers. 
9-GFP-Stat1-/- cells were rejected in both, wild-type C57BL/6 and UBQ-GFP transgenic mice, but not 
in IFN-γ-/- and Stat1-/- recipients.  
3.16 Lymphoma cells are lysed by NK cells in vitro 
Tumor cell killing by NK cells has been studied in various tumor models and has invariably 
been found to be dependent on absent or low MHC class I expression. As low MHC class I 
and class II expression is a hallmark of λ-hu-c-myc-induced lymphomas, we sought to 
determine whether there is any NK cell recognition in our model system. Most importantly, 
we found that Stat1 deficient lymphoma cells fail to upregulate MHC class I and class II 
molecules in the presence of IFN-γ, whereas Stat1-competent cells do respond to IFN-γ by 
upregulating MHC class I and class II as shown in figure 19. Therefore, we addressed the 
question whether the Stat1-competent (cell line 291) and the Stat1-deficient lymphoma cells 
(cell line 9) can serve as targets for NK cell lysis. 291-OVA-GFP Stat1-competent and 9-
OVA-GFP-Stat1-deficient cells were treated with murine IFN-γ and co-cultured with NK 
cells for 8 hours. YAC cells are mouse lymphoma cells and were described to be sensitive to 
the cytotoxic activity of NK cells. YAC cells were used as the positive control for NK cell 
lysis. As shown in figure 23, 65% of lysis was observed in 291-OVA cells in the absence of 
IFN-γ and lysis was reduced to 30 % upon treatment of 291-OVA cells with murine IFN-γ.  In 
contrast, IFN-γ treated Stat1-deficient 9-OVA cells were lysed significantly more efficiently 
than untreated 9-OVA cells. IFN-γ treatment of Stat1-competent lymphoma cells thus 
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diminished NK cell killing, whereas NK cell killing of Stat1-deficient lymphoma target cells 
was enhanced by IFN-γ treatment. However, it is important to note that both Stat1 competent 
(line 291-OVA) and Stat1 deficient (line 9-OVA) lymphoma cells were targets of NK cells 
and spontaneously sensitive to NK lysis. 
 
 
 
 
Figure 23  
291-OVA and 9-OVA lymphoma cells were both targets of spontaneous NK cell lysis. IFN-γ 
diminished NK cell killing in Stat1-competent cells and increased killing in Stat1 deficient 
lymphoma cells 
Stat1-competent 291-OVA-GFP cells and Stat1-deficient 9-OVA-GFP cells were treated with murine 
IFN-γ for 48 hours and co-cultured with NK cells. After 8 hours of co-culture with effector and target 
cells, the supernatants were removed and analyzed for LDH activity. IFN-γ treatment of 291-OVA-GFP 
cells led to diminished NK cell killing whereas IFN-γ treatment of 9-OVA-GFP cells increased NK cell 
killing of target cells. 
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4. Discussion 
4.1 MYC overexpression in human B cells imposes a non-immunogenic 
phenotype in vitro 
A major difference between EBV-positive BLs and LCLs is the level of expression of c-myc. 
Studies by Staege et al. pointed to the possibility that c-myc directly imposes the non-
immunogenic phenotype observed in BL cells (Staege et al., 2002). Besides the marked 
restriction of EBV antigen expression, there exists a selective down-regulation of some HLA 
class I alleles such as HLA-A11 (Imreh et al., 1995) and these cells exhibit a reduced 
capacity to process and present antigens in a HLA-restricted manner (Rowe et al., 1995; 
Frisan et al., 1998). In cell lines stably transfected with a constitutively active, Igκ-enhancer 
driven c-myc gene (A1 cells) (Polack et al., 1996) or with a tetracycline-controlled c-myc 
expression construct (P493-6 cells) (Pajic et al., 2000), overexpression of c-myc rendered 
proliferation independent of the viral proliferation program, and imposed the cell surface 
phenotype of BL cells. Studies from these conditional cell lines revealed that MHC class I, 
activation markers, and co-stimulatory molecules are highly downregulated during c-myc 
driven proliferation. Interestingly, c-myc driven cells had not only lost the allostimulatory 
capacity of the parental ER/EB2 cells in a mixed lymphocyte reaction, they also could not be 
recognized by antigen-specific CD8+ T cell clones even when they were forced to 
overexpress the cognate antigen by infection with recombinant vaccinia virus (Staege et al., 
2002). Furthermore, the peptide transporters such as TAP1 and TAP2 were also 
downregulated upon c-myc overexpression. The authors concluded that, in their in vitro 
system, B cells driven into proliferation through constitutive or conditional up-regulation of 
c-myc are immunologically silenced in the absence of any immune selection. The 
immunological silencing could be due to the cellular changes caused by c-myc up-regulation. 
These findings suggested that the outgrowth of poorly immunogenic tumors may not only be 
the consequence of an immunoediting process, but also may be caused by genetic alterations 
occurring during the transformation process. It was therefore important to know whether the 
effects of c-myc overexpression seen in the in vitro model can be recapitulated in an in vivo 
setting. 
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4.2 Mouse model to evaluate the immune response against a B cell lymphoma 
expressing a foreign antigen in vivo 
To elucidate if the observed effects of c-myc overexpression in vitro can be recapitulated in an 
in vivo setting, we took advantage of mice that are transgenic for c-myc. We wished to look 
for any evidence of immunological silencing by expressing foreign antigens in lymphomas 
established from these mice. Previous efforts to develop a mouse model centered on the 
generation of transgenic mice that express c-myc under the control of IgH regulatory 
sequences (Adams et al., 1985). However it is important to note that these constructs induced 
primarily precursor B cell as well as some surface Ig-positive B-cell lymphomas and in 
addition the transgenic mice displayed features of lymphoblastic lymphoma (LL) rather than 
of BL. Studies from Kovalchuk et al report that lymphomas with striking similarities to BL 
develop in mice bearing a MYC gene controlled by reconstructed Igλ locus (Kovalchuk et al., 
2000). Monoclonal IgM+ CD5- CD23- tumors developed and therefore these lymphoma 
bearing mice provide a better system for studying the pathogenesis of Burkitt’s lymphoma. 
Transgenic mice described above are usually considered as reliable mouse models of human 
cancer in comparison to carcinogen-induced cancer models which may not accurately mimic 
the spontaneous human tumor model (Prehn, 1975). 
We wished to address the immunological recognition of high grade B-cell lymphoma 
expressing the foreign antigens in vivo by transferring the lymphomas in immunocompetent 
mice. We selected chicken ovalbumin as a model foreign antigen because the introduction of 
ovalbumin does not alter the cell’s physiological condition. In addition, the availability of 
OVA-specific T cell tools makes it possible to study and quantify the T cell response against 
this antigen. After having established that transfer of 100.000 unmanipulated cells from a cell 
line (291) established from a spontaneous lymphoma (non transduced) led to 100% mortality, 
we analyzed whether or not the retroviral introduction of ovalbumin as foreign antigen leads 
to better immunological recognition and tumor rejection. Importantly retroviral transduction 
did not produce any notable effects in the expression of the major histocompatibility antigens.  
.  
4.3 Rejection of wild-type lymphoma cells is antigen dependent 
The observation that GFP- or OVA-GFP-transduced lymphoma cells were efficiently rejected 
upon transfer into wild-type mice implicated a protective role of the immune response against 
either GFP or ovalbumin protein. We found that the introduction of ovalbumin-bearing 
lymphomas led to delay in tumor development by ten days and to an increased survival 
compared to inoculation of unmanipulated parental lymphoma cells. The results of efficient 
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lymphoma rejection from OVA-bearing lymphomas were consistent both in wild-type mice 
and UBQ-GFP transgenic mice. It is also noteworthy that the introduction of GFP antigen 
alone led to an improved rejection when transferred in wild-type recipients but not in UBQ-
GFP transgenic mice which clearly indicated that GFP can act as an antigen and increases the 
immunogenicity of the lymphoma cells. GFP has been used as a potential marker in human 
clinical trials (Aran et al., 1998; Levenson et al., 1998). The mechanism for immune detection 
of cytoplasmic proteins like GFP is based on the ability of MHC to present processed 
antigenic peptides at the cell surface (Germain and Margulies, 1993). T cell receptors 
recognize antigen fragments associated with MHC. Studies from Stripecke et al. have 
demonstrated that the immune response to GFP may affect the outcome of gene transfer in an 
immunocompetent murine model (Stripecke et al., 1999). Their studies have shown that 
engraftment of leukemia and lymphoma cells in a murine host are significantly reduced when 
GFP is co-expressed. In addition, GFP expressing leukemia cells grew normally in Nu/Nu 
mice lacking functional T cells indicating the existence of a T cell response against GFP in 
wild-type mice. Furthermore, rejection of GFP-positive cells correlated with the appearance 
of CTL reacting specifically against cells expressing GFP. These results, together with our 
observation of rejection of GFP positive lymphomas, demonstrate the existence of potential 
antigenic peptides derived from GFP that could mediate lymphoma rejection. 
 In contrast to GFP, ovalbumin has been widely used as model antigen in a number of 
experimental mouse tumor models. In most of these tumor models ovalbumin was a weak 
antigen that did not lead to tumor rejection unless the mice were treated with stimulated 
OVA-specific T cells. Using EL4 thymoma as a tumor model, where EG7-OVA cells differ 
from the parental EL4 cells by expressing OVA, Zhou et al. demonstrated that OVA-specific 
CTLs elicited by vaccination can protect the mice against a subsequent tumor challenge (Zhou 
et al., 1992; Minev et al., 1994). Likewise, in a EL4 thymoma and a B16 melanoma lung 
metastasis model, transfer of antigen-stimulated ovalbumin-specific effector T cells was a 
prerequisite for tumor rejection (McCabe et al., 1995; Dobrzanski et al., 1999; Dobrzanski et 
al., 2000; Dobrzanski et al., 2004; Hollenbaugh et al., 2004). Given the low antigenicity of 
ovalbumin in these models, it was unforeseeable and surprising that ovalbumin as well as 
GFP acted as rejection antigens in this high grade B cell lymphoma model resulting in a 40-
45% increase in overall survival in recipient mice challenged with 291-OVA-GFP lymphoma 
cells. The role of antigen-specific T cells in lymphoma rejection was underlined by two 
additional observations: (i) we found increased numbers of SIINFEKL-specific CD8+ T cells 
in the splenocytes of wild type and UBQ-GFP mice challenged with OVA-GFP-expressing 
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tumor cells as compared to mice challenged with GFP-expressing tumor cells, (ii) mice, that 
developed delayed fatal lymphomas after inoculation of OVA-GFP expressing lymphoma 
cells, invariably displayed an antigen-loss phenotype, indicating that tumor cell variants were 
selected in outgrowing lymphomas. This may explain why approximately 55% of recipient 
mice develop tumors upon challenge with OVA-GFP bearing lymphoma cells. From these 
results it may be inferred that immunosurveillance can play an active role in suppressing or 
preventing the growth of tumors expressing a foreign antigen.  
 
In our B cell lymphoma model, the lymphoma cells expressed also the human c-MYC protein 
as a potential foreign antigen. According to peptide prediction algorithms potentially 
immunogenic epitopes could be predicted for the human c-MYC protein (data not shown). 
Yet, irrespective of potential epitopes in the human c-MYC protein, the inoculated 
unmanipulated 291 parental lymphoma cells grew progressively in both wild-type and UBQ-
GFP transgenic recipient mice and led to fatal tumor progression in 100% of the animals 
within 20 days. Thus in our model, the presence of human c-MYC protein appears not to be 
sufficient to induce an efficient immune response in an immunological competent host. 
Alternatively, it is also conceivable that the tumor cells grew too fast and outpaced a weak 
immune response against the human c-MYC protein when inoculated in numbers of 100.000 
lymphoma cells. Below the threshold of 100.000 cells injected, we observed variable 
engraftment of lymphoma, and below 10.000 cells all animals rejected the cells. Several 
reasons might account for the necessity to inoculate high cell numbers for tumor engraftment: 
(i) c-myc driven lymphomas exhibit a high degree of spontaneous apoptosis rendering tumor 
engraftment a potentially inefficient process, (ii) it is not known whether only a minor fraction 
of the cells or many or all cells in the tumor may act as tumor stem cells, (iii), in case that the 
majority of tumor cells has cancer stem cell properties, c-MYC protein may act as a weak 
antigen, and finally (iv) other mechanisms of rejection like the action of NK cells may be 
operating as well rendering the inoculation of a high number of tumor cells necessary. To 
address the potential immunogenicity of the human c-MYC protein, it will be necessary to 
study the efficiency of lymphoma engraftment/rejection in wild type mice that have been pre-
vaccinated with the human c-MYC protein. Such studies are in progress.  
 
The question remains why ovalbumin is such a weak antigen in the EL4 thymoma and B16 
melanoma models that can be recognized only after antigen-specific T cell stimulation 
((McCabe et al., 1995; Dobrzanski et al., 1999) and such a potent rejection antigen in our c-
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myc driven B cell lymphoma model. It is well known that membrane anchorage strongly 
increases the antigenicity of ovalbumin (Kurts et al., 1996). But this cannot account for the 
differences observed. In the EL4, B16, as well as in our c-myc driven lymphoma model it is 
the cytosolic version of ovalbumin that has been expressed. The most likely explanation for 
the differences observed in the various tumor models is that ovalbumin is expressed at much 
higher level after retroviral transduction as compared to the transfected EL4 and B16 cell 
lines expressing OVA at low level.  
 
In summary, our experiments have provided evidence that expression of foreign antigen 
(either GFP alone or OVA-GFP) in this B-cell lymphoma model led to immunological 
recognition, efficient tumor clearance, and increased survival in about half of the animals, and 
in delayed outgrowth of antigen-loss variants in the remaining mice. We have not yet defined 
the effector cell population that is mediating rejection of OVA-GFP expressing lymphomas. 
Given the increase in SIINFEKL-specific T cells after tumor inoculation, it is most likely that 
these CD8+ T cells also represent the effector cells mediating tumor rejection since 
SIINFEKL is the dominant peptide derived from OVA. This is also is supported by the notion 
that two different populations of OVA-specific cytotoxic CD8+ effector T cells mediate 
increased survival in the EL4 thymoma and the B16 melanoma models, one that secretes IFN-
γ (McCabe et al., 1995) and one that secretes IL-4, IL-5, and IL-10 (Dobrzanski et al., 2000). 
Whether the rejection of ovalbumin bearing lymphomas is dependent only on CD8+ T cells or 
requires additional immune effector cells, e.g. CD4+ T and/or NK cells, needs further 
attention and studies to address these questions are under investigation.  
 
4.4 Rejection requires the presence of IFN-γ and Stat1 signaling in the host 
The biology of IFN-γ and its role in transplantation immunity, tumor development and in 
cancer immunoediting processes are well documented (Ikeda et al., 2002; Blankenstein and 
Qin, 2003). IFN-γ contributes to the rejection of transplantable tumors and the inhibition of 
MCA-induced carcinogenesis by different mechanisms. To study the role of IFN-γR in tumor 
rejection, Blankenstein and co-workers used MCA-induced fibrosarcomas generated from 
IFN-γR KO mice and reconstituted IFN-γR expression in these cells. These studies 
demonstrated that IFN-γ receptor expression on tumor cells is not necessary for the generation 
of anti-tumor immunity, neither during the priming nor the effector phase (Qin and 
Blankenstein, 2000). Schreiber and colleagues reported that endogenously produced IFN-γ 
forms the basis of the tumor surveillance system that controls both chemically induced and 
 69
spontaneously arising tumors in mice. Using tumor cells derived from MCA-treated IFN-γ 
unresponsive mice, the authors found that IFN-γ directly impinges on the immunogenicity of 
the tumor (Kaplan et al., 1998; Shankaran et al., 2001; Dunn et al., 2004). The importance of 
IFN-γ is emphasized by the finding that the lack of IFN-γ sensitivity predisposes the mice to 
enhanced tumor development (Shankaran et al., 2001). Therefore, one of the roles played by 
IFN-γ is at the level of the tumor cell, presumably by up-regulating the MHC molecules 
and/or antigen processing machinery. It is also important to note that in the human c-myc 
overexpressing cell line A1, interferon inducible components of the proteasome, namely 
lmp2, lmp7, PA28α, and PA28β, are significantly down-regulated as compared to the parental 
EREB2-5 cells. Furthermore, both components of the peptide transporter complex TAP1 and 
TAP2 are expressed at very low level in these cells indicating that c-myc overexpression 
impairs antigen processing and presentation which – in addition to downregulation of MHC, 
adhesion and costimulatory molecules - might contribute to the non-immunogenic phenotype 
of c-myc overexpressing cells (Staege et al., 2002). Consistent with this, the proteasomal 
composition is altered and the proteasomal activity decreased and shifted towards 
chymotrypsin-like substrates in these cells (Frisan et al., 1998; Gavioli et al., 2001). 
 
Most of the experiments validating the cancer immunoediting hypothesis have been 
performed using MCA-induced chemical carcinogenesis. The finding that ovalbumin 
transduced lymphomas are rejected by the immune system raises the following questions: 
Firstly, which are the molecular mechanisms leading to the rejection of ovalbumin-expressing 
lymphomas, and secondly, what is the contribution of cells of the innate and of the adaptive 
immune system in tumor rejection? It is noteworthy that type I interferons are also involved in 
upregulation of MHC molecules. Recently, an important role of type I interferons has been 
demonstrated in the rejection of highly immunogenic unedited MCA-induced sarcomas which 
required IFN-α/β responsiveness at the level of hematopoetic cells (Dunn et al., 2005).  
In order to address the possible contribution of interferon signaling in tumor rejection, we 
took advantage of both Stat1-/- and IFN-γ-/- recipient mice in tumor transfer experiments. We 
further dissected the cellular and molecular mechanisms behind OVA-GFP lymphoma 
rejection. Consistent with the previous findings, we found that transfer of OVA-GFP 
lymphoma cells in IFN-γ-/- and Stat1-/- recipient mice increased tumor growth and decreased 
overall survival, indicating that lymphoma rejection is associated with host IFN-γ production 
and Stat1 signaling. One potential reason for the failure of Stat1-/- mice to recognize 
ovalbumin transduced lymphomas was that antigen loss variants were selected (measured by 
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GFP expression). However, GFP expression and therefore ovalbumin expression was 
preserved in developing lymphomas from Stat1-/- and IFN-γ-/- mice. Thus, unlike in wild-type 
recipient mice, no selection of antigen-loss variants appeared to occur in Stat1-/- and IFN-γ-/- 
mice. This is consistent with a previous study in which Stat1-/- mice failed to reject 
immunogenic tumors and did not support regression of poorly immunogenic tumors when 
treated with an IL-12 based vaccine (Fallarino and Gajewski, 1999). The authors concluded 
that the lack of rejection was due to decreased production of IFN-γ from T cells of Stat1-/- 
mice and that these T cells lacked the cytolytic activity seen in wild-type mice. The authors 
reported furthermore, that NK cells are not functional in Stat1-/- mice. Lack of NK cell 
function may further contribute to the fast outgrowth of lymphomas inoculated into Stat1-/- 
mice, but this possibility has not been further pursued in this work. 
 
To assess the possible reason for the failure to reject OVA-GFP expressing tumors in Stat1-/- 
and IFN-γ -/- mice, we evaluated expression of H-2Kb (MHC class I) and IAb (MHC class II) 
in developing ovalbumin-transduced lymphomas from wild-type, Stat1-/- and IFN-γ-/- recipient 
mice. We found that H-2Kb and IAb expression is increased only in developing lymphomas 
from wild-type but not from Stat1-/- and IFN-γ -/- recipient mice. This supports the notion that 
IFN-γ mediated upregulation of MHC class I and MHC class II molecules is associated with 
lymphoma rejection. A recent study has highlighted the importance of IFN-γ mediated 
upregulation of MHC for the rejection of a minor antigen-expressing tumor. Meunier et al. 
showed that injection of CD8+ T cells primed against immunodominant H7a minor H antigen 
could cure established melanomas in mice. These studies demonstrated IFN-γ released into 
the tumor is crucial for tumor rejection for two reasons: it increased MHC class I expression 
on tumor cells and inhibited angiogenesis (Meunier et al., 2005). Whether IFN-γ also 
suppresses angiogenesis in our tumor model needs further investigation. In our model, it is 
evident that upregulation of MHC expression in lymphoma cells is associated with tumor 
rejection. The importance of MHC class I upregulation for rejection of OVA-GFP expressing 
lymphomas in wild type mice was further supported by the finding that OVA-GFP expressing 
lymphomas exhibited consistently higher levels of MHC class I and II expression when 
analysed ex vivo as compared to the parental OVA-GFP expressing cells cultured in vitro. 
Importantly, MHC class I and II expression decreased to the initial level when the tumors 
were explanted and cultivated again in vitro. Upregulation of MHC class I and II expression 
could be recapitulated by addition of IFN-γ to cultured OVA-GFP expressing 291 lymphoma 
cells in vitro. Taken together, our data demonstrate that host IFN-γ and Stat1 signaling within 
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host immune cells play an important role in the rejection of foreign antigen expressing 
lymphomas. 
Having demonstrated unequivocally that c-myc driven murine lymphomas expressing OVA-
GFP or GFP are recognized and rejected by the adaptive immune system the question remains 
why murine lymphoma cells expressing foreign antigens are efficiently recognized by the 
adaptive immune system whereas Burkitt’s lymphoma cells expressing Epstein-Barr viral 
antigens are not. The data from the murine in vivo model clearly show that rejection is 
associated with upregulation of MHC class I on the tumor cells in vivo. Murine lymphoma 
cells cultivated in vitro have furthermore retained the ability to respond to IFN-γ by 
upregulation of MHC molecules. In this regard it is interesting to note that human Burkitt’s 
lymphoma cells have lost the ability to upregulate MHC class I molecules in response to IFN-
γ. Many EBV-positive Burkitt’s lymphoma lines have furthermore developed resistance to 
IFN-γ taking STAT1 tyrosine 701 phosphorylation as a readout. In many of these cell lines 
the molecular basis for this partial or complete IFN-γ resistance has been molecularly defined 
and found to be linked to JAK2 downregulation (Judith Mergler, Ph.D. thesis, 2008, 
Department of Biology of the LMU Munich). Downregulation of JAK2 has also been found 
to be a hallmark of the Burkitt’s lymphoma gene expression signature in two studies 
comparing gene expression profiles of Burkitt´s lymphoma (BL) and diffuse large B cell 
lymphomas (Dave et al., 2006; Hummel et al., 2006). These findings suggest that loss of IFN-
γ responsiveness is a prerequisite for development of lymphomas expressing foreign antigens. 
We will address this question experimentally by studying engraftment versus rejection of 
OVA-GFP expressing lymphomas that have either retained or lost the ability to respond to 
IFN-γ. To this end, λ-hu-cmyc transgenic mice are being crossed to IFNGR-/- mice. 
 
4.5 Induction of antigen-specific CD8+ T cell tolerance in B cell lymphoma 
The priming of tumor antigen-specific T cells is an important prerequisite for tumor rejection 
(Fallarino and Gajewski, 1999). It is known that adoptive transfer of antigen-specific T cells 
prior to tumor establishment can result in efficient tumor rejection (Cheever et al., 1980; 
Gattinoni et al., 2006). Studies from mouse models involving immunization against OVA 
antigen (Minev et al., 1994) or adoptive transfer of CD8+ T cells directed against ovalbumin 
(McCabe et al., 1995) indicated that the transfer of ovalbumin specific CD8 + T cells results 
in significant reduction of tumor burden in mice. We observed, however, in our tumor model 
that ovalbumin-transduced lymphoma cells growing in Stat1-/- mice were not affected by the 
adoptive transfer of either naïve or primed antigen-specific OT-I cells. The finding that 
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transfer of either naïve or primed antigen-specific OT-I CD8+ T cells failed to induce 
protective immune response against ovalbumin-transduced lymphoma cells was surprising. 
Considering the experimental details, it is important to note that the number of transferred 
primed OT-I CD8+ T cells was 10-fold higher then the injected tumor cells. This finding 
strongly suggests that the tumor is able to induce T cell anergy or tolerance. Additional 
experiments in our model provided evidence that a large population of transferred primed OT-
I T cells persisted in vivo whereas naive OT-I T cells did not. Paradoxically, the presence of 
transferred OT-I CD8+ T cells did not lead to tumor rejection in Stat1-/- recipients. Similar 
results have been reported in the A20 B cell lymphoma and in a metastatic melanoma model. 
Naïve CD4+ T cells specific for an antigen expressed by the tumor cells were rendered 
anergic early during tumorigenesis in the A20 B cell lymphoma model (Staveley-O'Carroll et 
al., 1998). Likewise, transfer of high numbers of antigen-specific CD8+ T cells into the 
tumor-bearing host did not induce an efficient immune response against the tumor indicating 
that transfer of antigen specific CD8+ T cells alone is not enough to induce anti-tumor 
immunity (Overwijk et al., 2003). An alternative explanation for these findings is the 
induction of antigen-specific T cell unresponsiveness early in the course of tumor-T cell 
interactions.  
A similar state of T cell anergy has been demonstrated in animals and patients harboring large 
tumor burdens as demonstrated by the impaired response against recall antigens in vivo. The 
identification of antigen-specific T cell anergy as an early event in tumor progression has 
clear implications for the future development of cancer immunotherapy. For the design of 
efficacious immunotherapeutic approaches it remains a major challenge to identify the 
molecular basis of lymphoma-induced T cell anergy and to develop strategies to restore T cell 
responsiveness. 
 
4.6 Generation of Stat1-deficient B cell lymphomas  
In the next part of our studies, we focussed on lymphoma cells that are devoid of Stat1, a key 
protein in IFN signaling. Experiments performed in different experimental models have 
provided evidence that tumors are the targets of IFN-γ and have validated the concept of IFN-
γ as an extrinsic tumor suppressor (Kaplan et al., 1998; Shankaran et al., 2001). It has, 
however, remained open whether the tumor cells themselves or host cells are the targets of 
IFN-γ mediating an antitumoral effect. IFN-γ insensitive but not IFN-responsive Meth A 
tumors grew progressively when transferred into syngeneic recipients (Dighe et al., 1994) 
suggesting that the increased tumorigenicity of IFN-γ insensitive Meth A tumor cells is due to 
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decreased immunogenicity of the tumor cells. Of note, IFN-γ insensitive Meth A tumors 
failed to prime anti-Meth A immunity in naïve mice and were not rejected in mice that had 
been vaccinated with wild type tumor cells (Dighe et al., 1994). These studies highlighted that 
tumor cells are targets of IFN-γ. However, studies by several groups have stressed the point 
that not the tumor cells, but host stroma or phagocytic cells, are the important target cells for 
IFN-γ to mediate an antitumor response (Mumberg et al., 1999; Pulaski et al., 2002; Segal et 
al., 2002; Qin et al., 2003). Surprisingly, the question of whether tumors are targets of 
interferons has been addressed almost exclusively in MCA induced carcinogenesis models 
and not in oncogene induced tumor settings.  
 
Since type I as well as type II interferons can upregulate MHC class I and class II and thereby 
augment tumor immunogenicity, we have addressed (i) whether c-myc over-expressing high 
grade lymphomas are direct targets of IFNs, and (ii) whether Stat1 competence is a 
prerequisite for rejection of OVA-GFP expressing lymphoma cells. To this end, we have 
crossed the λ-hu-c-myc transgene onto Stat1-/- mice and established Stat1-deficient c-myc-
induced lymphomas. Lymphomas developed slightly faster on Stat1-deficient as compared to 
wild-type background, and the effect appeared to be significant.  
To study the role of Stat1-deficiency exclusively at the level of the tumor cell and not the 
host, Stat1-competent (IFN responsive) and Stat1-deficient lymphoma cell lines (IFN 
unresponsive) were established from lymphoma bearing mice, in which both, the type I and 
type II interferon signaling pathways are either functional or abrogated. As expected, 
treatment of Stat1-/- lymphoma cells with IFN-γ did not increase MHC class I and MHC class 
II expression in vitro.  
 
 
4.7 Stat1-deficient B cell lymphomas are rejected in wild type recipient mice 
and this rejection is antigen independent 
If rejection of an antigen expressing tumor requires IFN-responsiveness of the tumor cell, the 
transfer of OVA-GFP expressing Stat1-/- lymphomas into wild-type mice should lead to 
accelerated tumor growth. To test this hypothesis, Stat1-competent cells (cell line 291) and 
Stat1-deficient cells (line 9) were transduced with OVA-GFP and injected into UBQ-GFP 
transgenic recipient mice. Paradoxically, antigen expressing Stat1-deficient cells were 
efficiently rejected in wild-type mice and, upon longer follow up, no antigen loss variants 
grew out. This unexpected finding raised two questions: Firstly, is the rejection of Stat-1-
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deficient lymphoma cells antigen-dependent? And secondly, what is the mechanism 
responsible for the rejection of IFN unresponsive lymphomas? To address the first question, 
GFP-transduced Stat1-deficient lymphoma cells were inoculated into UBQ-GFP transgenic 
mice and equally rejected in the same manner as the OVA-GFP expressing lymphoma cells. 
These results imply that the rejection of Stat1-deficient lymphoma cells in UBQ-GFP 
transgenic mice is antigen-independent. As Stat1-competent lymphomas form tumors in the 
same host, and Stat1-deficient lymphomas are rejected, Stat1 may be regarded as an oncogene 
in this experimental setting.  
In a recent study Kovacic et al. came to a similar conclusion using two different murine 
myeloid leukemia models. These authors demonstrated that lack of Stat1 decreased v-abl- or 
Jak2/Tel-induced myeloid leukemogenesis and provided evidence that retrovirally transduced 
Stat1-/- cells, but not Stat1+/- cells, have been efficiently eliminated in immunodeficient Rag2-/- 
mice by NK cells. The authors demonstrated that efficient NK cell lysis and tumor clearance 
is dependent on low MHC class I protein levels of Stat1-/- tumor cells and can be efficiently 
inhibited by exogenous MHC class I expression(Kovacic et al., 2006).  
The similarities between the two experimental systems strongly suggests that rejection of 
OVA-GFP or GFP-expressing Stat1-/- lymphoma cells in wild type or UBQ-GFP transgenic 
mice is mediated by NK cell lysis.  
 
4.8 Rejection of Stat1-deficient B cell lymphomas is dependent upon IFN-γ 
We next addressed the question whether Stat1-deficient lymphoma cells have lost their 
oncogenic potential or whether they have remained oncogenic when inoculated into Stat1-/- 
and IFN-γ-/- recipient mice. Inoculation of Stat1-deficient lymphoma cells in Stat1-/- and IFN-
γ-/- recipient mice resulted in efficient and rapid tumor formation. This ruled out the 
possibility that Stat1 deficient cells engrafted less efficiently in vivo. Rather, Stat1 deficient 
cells are targets for immune attack. Importantly, both the rejection of OVA-GFP expressing 
Stat1 competent lymphomas in an antigen-dependent manner and rejection of Stat1 deficient 
lymphoma cells in an antigen-independent manner required host IFN-γ signaling. This 
supports the notion of an extrinsic tumor suppressor function of IFN-γ. Mice with disruptions 
in genes encoding proteins that play a critical role in either IFN-γ receptor signaling (IFNGR1 
or Stat1) or lymphocyte development (Rag2) displayed increased incidence and kinetics of 
MCA-dependent tumor induction compared to wild-type counterparts (Shankaran et al., 
2001). Taken together, our results revealed that IFN-γ played an indispensable role in tumor 
rejection. Although the concept of IFN-γ mediated tumor immunosurveillance is widely 
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accepted, it is still not known which cells are responsible for producing IFN-γ during the anti-
tumoral immune response. Different immune cells, specifically NKT cells, γδ T cells and NK 
cells may be the first to recognize the developing tumors. Many of these cells involved in 
innate immunity can also produce higher amounts of IFN-γ during early recognition before 
tumor recognition by the adaptive immune system is initiated. 
The finding that Stat1-deficient lymphomas are rejected in an antigen-independent manner in 
wild type mice raised two important questions: Firstly, are Stat1-deficient lymphoma cells 
direct targets for NK cell lysis? And secondly, is there a role for NK cells in the development 
of spontaneous lymphomas in wild type mice?   
 
4.9 Lymphomas are sensitive to NK-cell mediated cytolysis in vitro, but IFN-γ 
decreases NK cell sensitivity through induction of MHC-class I expression on 
lymphoma targets 
The finding that Stat1-deficient cells are unresponsive to IFN-γ, fail to induce MHC class I 
expression and are rejected in wild type mice gave the first indication that NK cells might 
play an important role in tumor surveillance in our experimental model system. This 
conclusion was strongly supported by the recent data of Kovacic et al. who showed that Stat1-
/- leukemic cells are cleared by NK cells due to low MHC class I expression (Kovacic et al., 
2006). This raised the possibility that NK cells might play a role also in the 
immunosurveillance of spontaneously arising lymphomas in λ-hu-cmyc transgenic mice. The 
following points support this notion: (i) c-MYC strongly downregulates MHC class I 
expression, (ii) MHC class I expression appears to be higher on tumor cells ex vivo than on 
the parental cells in culture that have been inoculated to generate the tumor.  
We therefore asked whether Stat1-competent and Stat1-deficient cells can be directly 
recognized by NK cells in vitro, and if so, whether and how cytolysis is affected by IFN-γ 
treatment. We showed that Stat1-competent as well as Stat1-deficient lymphoma cells were 
direct targets of NK cells and could be lysed efficiently in vitro. IFN-γ treatment increased 
MHC expression and decreased NK cell mediated lysis of Stat1-competent lymphoma cells in 
vitro, whereas IFN-γ - without affecting MHC class I expression on Stat1-deficient tumor 
cells - increased the lysis of these cells, by either activating the cytotoxic potential of NK 
cells, by inducing the expression of NK activating ligands on the tumor cells or both. These 
results suggest that NK cells may play an important role in the rejection of Stat1-competent as 
well as of Stat1-deficient lymphoma cells not only in vitro but also in vivo. IFN-γ might play 
a dual role in this experimental setting depending on whether the tumor expresses foreign 
antigens and is immunogenic or not. If the tumor is immunogenic, upregulation of MHC class 
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I molecules on Stat1-competent lymphomas by IFN-γ might facilitate the recognition and 
rejection of the lymphoma cells by the adaptive arm of the immune system in wild-type mice. 
If the tumor cells are not immunogenic, they might be initially recognized by NK cells. The 
IFN-γ produced by activated NK cells might upregulate MHC class I expression on remaining 
tumor cells in a paracrine fashion thus protecting the tumor cells from further NK cell attack. 
Such a model is compatible with the finding that (i) Stat1-competent lymphoma cells are 
recognized by NK cells in vitro, although they form tumors efficiently in vivo, and (ii) that 
Stat1 deletion does not dramatically accelerate tumor development in vivo although the NK 
barrier is missing. A testable prediction of this concept would be that λ-hu-myc transgenic 
lymphoma cells might be less oncogenic in IFN-γ-/- than in wild type mice.  
 
4.10 NK cell-dependent innate immunosurveillance in B cell lymphomas in 
vivo 
The concept of cancer immunoediting has mostly focused on the adaptive arm of immune 
system. A potential involvement of innate immune cells has only recently emerged. Studies 
performed using B cell lymphomas spontaneously arising in immunocompromised mice 
(IFN-γ-, β2-microglobulin and/or perforin deficient) have shown that the rejection of the 
tumors is mediated by NK and γδ T cells (Street et al., 2002; Street et al., 2004). Most 
importantly, depletion of either CD4+ T cells or CD8+ T cells or both populations in wild-
type mice did not prevent the rejection of spontaneously arising B cell lymphomas (Street et 
al., 2002). These elegant studies have demonstrated the potential involvement of NK cells in 
tumor surveillance. A more recent study has shown that low expression of MHC class I on 
Stat1-/- tumor cells causes efficient lysis and enhanced clearance of Stat1-/- leukemias by NK 
cells (Kovacic et al., 2006). To demonstrate that rejection of Stat1-/- leukemic cells depended 
on NK cells, the authors increased MHC class I levels on tumor cells by retroviral 
transduction and found that the tumor cells became resistant to NK mediated rejection. As a 
consequence, Stat1-/- tumor cells transduced with MHC class I gave rise to leukemic disease 
that progressed almost as rapidly as Stat1-expressing tumor cells (Kovacic et al., 2006). This 
observation is also consistent with earlier studies showing that B cell malignancies are 
predominantly under NK cell-mediated innate immunosurveillance (Cerwenka et al., 2000; 
Stoiber et al., 2004; Street et al., 2004). 
The susceptibility of tumor cells to NK cell-mediated killing is thought to be determined by 
the relative expression of ligands for NK-activating and inhibitory receptors (Vivier and 
Anfossi, 2004; Vivier et al., 2004). NKG2D is an activating receptor expressed on human and 
 77
mouse NK cells that recognizes the Rae-1 family of proteins, H60 and MULT1 in mice, and 
MICA proteins in humans (Cerwenka et al., 2001; Jamieson et al., 2002; Raulet, 2003). 
NKG2D ligands are not expressed on the surface of normal cells but are upregulated on many 
primary tumors, many tumor cell lines and some carcinogen-induced tumors (Diefenbach et 
al., 2000). A hallmark of many tumor cells is genomic instability and one pathway that has 
been implicated in the induction of these genes is the DNA-damage response (Gasser et al., 
2005). Consistent with these findings, transfected tumor cell lines expressing NKG2D ligands 
were rejected in vivo in an NKG2D-dependent manner (Cerwenka et al., 2001; Diefenbach et 
al., 2001; Diefenbach and Raulet, 2001). However, examples in which tumors have evaded 
NKG2D surveillance have also been described (Groh et al., 2002; Coudert et al., 2005; 
Oppenheim et al., 2005).  
A recent study has demonstrated that NKG2D-mediated immunoediting occurs in c-myc 
overexpressing B cell lymphomas (Gasser et al., 2005). This study has provided genetic 
evidence for the recognition of primary tumors by NK cells. Using transgenic NKG2D-
deficient TRAMP mice, Guerra et al. demonstrated that NKG2D plays an important role in 
tumor immunosurveillance in a model of prostate adenocarcinoma and in Eµ-myc transgenic 
mice. Oncogene-induced stress as a result of c-myc overexpression is known to activate the 
DNA-damage response pathway (Dominguez-Sola et al., 2007; Reimann et al., 2007), which 
might cause up-regulation of NKG2D ligands during early tumorigenesis and may cause 
recognition of developing tumor cells in a NKG2D-dependent fashion. Another study has 
provided evidence that NKG2D ligands are induced on spontaneously arising tumors in a 
murine model of lymphomagenesis and that c-myc is involved in this up-regulation (Unni et 
al., 2008). Thus, the above two recent studies suggest that up-regulation of NKG2D ligands 
by oncogenic transformation sensitizes the cells for immune recognition by NK cells. 
4.11 How is the NK cell barrier overcome in naturally arising tumors?  
If NK cells indeed do play such an important role, the question remains how this barrier is 
overcome in the course of spontaneously arising tumors, including those developing in Eµ-
myc or λ-hu-c-myc transgenic mice. One apparent mechanism appears to be that constitutive 
expression of NK activating ligands on tumor cells will induce downregulation of NKG2D 
receptors on NK cells and will thus lead to desensitization of NK cells (Groh et al., 2002; 
Oppenheim et al., 2005; Coudert et al., 2005, 2008; Unni et al., 2008). Interestingly, although 
constitutive encounter of activating ligands significantly impaired the cytotoxicity of NK cells 
in the NK-sensitive RMA-S T cell lymphoma model, it led to constitutive IFNγ production of 
NK cells (Coudert et al., 2008).  
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Our data suggested an important role for STAT1 not only in T cell-mediated rejection of 
tumors expressing foreign antigens, STAT1 acted also as an oncogene and was required for 
outgrowth of a tumor in an immunocompetent host. The finding that STAT1-deficient 
lymphomas were rejected in an antigen-independent manner strongly suggested an important 
role for NK cells in this experimental setting. Yet, as STAT1-competent lymphomas were not 
rejected in wild type recipients, a possible role of NK cells in the control of STAT1-
competent lymphomas was much less evident and has emerged only recently when STAT1 –
deficient and STAT1-competent lypmphomas were compared. Outgrowth of STAT1-
competent lymphomas was associated with MHC class I upregulation in vivo. It is tempting to 
speculate that increased MHC class I expression has been selected for in vivo to inactivate 
NK cells. It will be important to repeat these tumor inoculation experiments with Rag1-/- 
mice that lack B and T cells but harbor functional NK cells, and after inoculation into wild 
type mice in which distinct cell populations like e.g. NK cells have been deleted by 
monoclonal antibodies.  
It will be particularly interesting to address te question whether constitutive upregulation of 
MHC class I in λ-hu-c-myc transgenic mice will accelerate spontaneous lymphoma 
development. Likewise, it will be most interesting to see whether host IFNγ is required for 
outgrowth of STAT1-competent lymphomas by increasing MHC class I expression on the 
tumor cells above a critical threshold that is required to inactivate NK cells. To address these 
questions two reciprocal experimental approaches will be taken: (i) inoculation of STAT1-
competent lymphomas into IFNγ-/- recipient mice and (ii) conversely, inoculation of IFNγ-
unresponsive (IFNGR-/-) lymphomas into wild type recipient mice. Likewise, spontaneous 
tumor development will be monitored in λ-hu-c-myc transgenic mice that lack either IFNγ or 
the IFNγ receptor.  
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